# Core Task
Analyze the provided literature to classify the therapeutic biomarker (ThMAR) CRP (also known as PTX1) into one of the following five types:
1. Pharmacodynamic biomarker (PDY)
2. Safety biomarker (SAF)
3. Monitoring biomarker (MOI)
4. Predictive biomarker (PRD)
5. Surrogate endpoint (SUR)

The definition, importance, and typical examples of each ThMAR type are explicitly described in the image `dataset\TheMarker\ThMARs_TYPE.png`.
Literature to analyze: `dataset\TheMarker\34903842.pdf`, `dataset\TheMarker\25135077.pdf`, `dataset\TheMarker\30289572.pdf`, `dataset\TheMarker\19435794.pdf`,
`dataset\TheMarker\FDA.pdf`

# Output Requirements & File Path
- Output format: A JSON list of dictionaries with "PMID" and "TypeID".
- "PMID" is the filename(For FDA.pdf, "PMID" is "FDA"), and "TypeID" is the classification category mentioned above (int).
- Save Path: Save the complete list to: `/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/themarker_extract_1.json`
- Intermediate Storage Path: All intermediate code generated during execution, downloaded files, and temporary results must be stored in `/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/`

# Example Output (For Reference Only)
[
  {
      "PMID": "22222222",
      "TypeID": 2
  },
  {
      "PMID": "33333333",
      "TypeID": 4
  }
]

I'll start by creating a plan for this task and then execute it step by step.

**Plan:**
1. [ ] Create the intermediate storage directory
2. [ ] Read the ThMARs_TYPE.png to understand the definitions of each biomarker type
3. [ ] Read and analyze each PDF file to classify CRP (PTX1)
4. [ ] Compile the results into JSON format
5. [ ] Save the final JSON file to the specified path

Let me start by creating the directory and reading the definitions:

<execute>
import os
import json

# Create intermediate storage directory
tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/"
os.makedirs(tmp_dir, exist_ok=True)
print(f"Created directory: {tmp_dir}")

# List the files we need to analyze
dataset_dir = "dataset/TheMarker/"
files_to_analyze = [
    "34903842.pdf",
    "25135077.pdf", 
    "30289572.pdf",
    "19435794.pdf",
    "FDA.pdf"
]

print("Files to analyze:")
for f in files_to_analyze:
    full_path = os.path.join(dataset_dir, f)
    exists = os.path.exists(full_path)
    print(f"  - {full_path}: {'EXISTS' if exists else 'NOT FOUND'}")
</execute>
<observation>Created directory: /root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/
Files to analyze:
  - dataset/TheMarker/34903842.pdf: NOT FOUND
  - dataset/TheMarker/25135077.pdf: NOT FOUND
  - dataset/TheMarker/30289572.pdf: NOT FOUND
  - dataset/TheMarker/19435794.pdf: NOT FOUND
  - dataset/TheMarker/FDA.pdf: NOT FOUND
</observation>
<execute>
import os

# Check current directory
print("Current directory contents:")
for root, dirs, files in os.walk("."):
    for file in files:
        if "TheMarker" in root or "dataset" in root or "pdf" in file.lower() or "png" in file.lower():
            print(f"  {os.path.join(root, file)}")

print("\n---")

# Check database_lake
print("Database lake contents:")
for root, dirs, files in os.walk("./operation_env/database_lake"):
    for file in files:
        print(f"  {os.path.join(root, file)}")
</execute>
<observation>The output is too long to be added to context. Here are the first 10K characters...
Current directory contents:
  ./benchmark/dataset/ADCdb/ref2.pdf
  ./benchmark/dataset/ADCdb/ref4.pdf
  ./benchmark/dataset/ADCdb/ref5.pdf
  ./benchmark/dataset/ASMdb/SRR942022.html
  ./benchmark/dataset/ASMdb/SRR942022.json
  ./benchmark/dataset/ASMdb/SRR942022.sam
  ./benchmark/dataset/ASMdb/SRR942022_clean.fastq
  ./benchmark/dataset/ASMdb/sample.sorted.deduplicated.bam
  ./benchmark/dataset/ASMdb/sample.sorted.deduplication_report.txt
  ./benchmark/dataset/ASMdb/meth/CHG_context_sample.sorted.txt
  ./benchmark/dataset/ASMdb/meth/CHH_context_sample.sorted.txt
  ./benchmark/dataset/ASMdb/meth/CpG.methratio.effective.tsv
  ./benchmark/dataset/ASMdb/meth/CpG.methratio.tsv
  ./benchmark/dataset/ASMdb/meth/CpG_context_sample.sorted.txt
  ./benchmark/dataset/ASMdb/meth/sample.sorted.M-bias.txt
  ./benchmark/dataset/ASMdb/meth/sample.sorted.bedGraph.gz
  ./benchmark/dataset/ASMdb/meth/sample.sorted.bismark.cov.gz
  ./benchmark/dataset/ASMdb/meth/sample.sorted_splitting_report.txt
  ./benchmark/dataset/ASMdb/mock/mock_asm_sites.csv
  ./benchmark/dataset/ASMdb/mock/mock_genes.csv
  ./benchmark/dataset/ASMdb/ref/TAIR10_chr_all.fas
  ./benchmark/dataset/ASMdb/ref/TAIR10_chr_all.fas.batmeth2.fa.amb
  ./benchmark/dataset/ASMdb/ref/TAIR10_chr_all.fas.batmeth2.fa.ann
  ./benchmark/dataset/ASMdb/ref/TAIR10_chr_all.fas.batmeth2.fa.bwt
  ./benchmark/dataset/ASMdb/ref/TAIR10_chr_all.fas.batmeth2.fa.pac
  ./benchmark/dataset/ASMdb/ref/TAIR10_chr_all.fas.batmeth2.fa.sa
  ./benchmark/dataset/ASMdb/ref/TAIR10_chr_all.fas.bin
  ./benchmark/dataset/ASMdb/ref/TAIR10_chr_all.fas.len
  ./benchmark/dataset/ASMdb/rna_seq/SRR942022_1.fastq
  ./benchmark/dataset/ASMdb/toy_bed/mini_test.bed
  ./benchmark/dataset/ASMdb/toy_srr/SRR534266_1.fastq.gz
  ./benchmark/dataset/BioKA/paper_content.md
  ./benchmark/dataset/COLOCdb/GCST90000064_buildGRCh37.tsv
  ./benchmark/dataset/COLOCdb/hg19ToHg38.over.chain.gz
  ./benchmark/dataset/COLOCdb/temp_input.bed
  ./benchmark/dataset/COLOCdb/temp_output.bed
  ./benchmark/dataset/COLOCdb/temp_unmapped.bed
  ./benchmark/dataset/COVID-19/GPL23159-184565.txt
  ./benchmark/dataset/COVID-19/id2hgnc.json
  ./benchmark/dataset/COVID-19/GSE153428/GSE153428_RAW.tar
  ./benchmark/dataset/COVID-19/GSE153428/GSE153428_family.soft.gz
  ./benchmark/dataset/COVID-19/GSE153428/GSE153428_family.xml.tgz
  ./benchmark/dataset/COVID-19/GSE153428/GSE153428_series_matrix.txt
  ./benchmark/dataset/COVID-19/GSE154769/GSE154769_family.soft.gz
  ./benchmark/dataset/COVID-19/GSE154769/GSE154769_family.xml.tgz
  ./benchmark/dataset/COVID-19/GSE154769/GSE154769_longitudinal_raw_counts.txt
  ./benchmark/dataset/COVID-19/GSE154769/GSE154769_series_matrix.txt
  ./benchmark/dataset/CancerMIRNome/circulating_miRNome_abundance.csv
  ./benchmark/dataset/CancerProteome/cancer_proteome.csv
  ./benchmark/dataset/CancerProteome/protein_abundance.csv
  ./benchmark/dataset/CancerProteome/transcript_levels.csv
  ./benchmark/dataset/CancerSCEM/CellMarker.csv
  ./benchmark/dataset/CancerSCEM/cell_1.txt
  ./benchmark/dataset/CancerSCEM/gene_expression.csv
  ./benchmark/dataset/CellCommuNet/pbmc3k_raw.h5ad
  ./benchmark/dataset/CellSTAR/cellstar_integration.csv
  ./benchmark/dataset/ClinicalOmicsDB/expression_data.csv
  ./benchmark/dataset/CompoDynamics/GCF_009428885.1_ASM942888v1_cds_from_genomic.fna
  ./benchmark/dataset/CompoDynamics/GCF_009428885.1_ASM942888v1_cds_from_genomic.fna.fai
  ./benchmark/dataset/CompoDynamics/GCF_009428885.1_ASM942888v1_genomic.gff
  ./benchmark/dataset/CompoDynamics/raw_cds.fna
  ./benchmark/dataset/CompoDynamics/GCF_000007005.1/amino_acid
  ./benchmark/dataset/CompoDynamics/GCF_000007005.1/coding_potential
  ./benchmark/dataset/CompoDynamics/GCF_000007005.1/codon
  ./benchmark/dataset/CompoDynamics/GCF_000007005.1/nucleotide
  ./benchmark/dataset/CompoDynamics/GCF_000007005.1/phase_separation
  ./benchmark/dataset/CompoDynamics/GCF_000007005.1/physicochemical_property
  ./benchmark/dataset/CovPDB/cov_pdb_ids.json
  ./benchmark/dataset/CovPDB/ligand_list
  ./benchmark/dataset/CovPDB/pdf_content.md
  ./benchmark/dataset/CovPDB/prepare_input_structures.py
  ./benchmark/dataset/CovPDB/complex_structures/5yuv.cif
  ./benchmark/dataset/CovPDB/complex_structures/6a1f.cif
  ./benchmark/dataset/CovPDB/complex_structures/6a1g.cif
  ./benchmark/dataset/CovPDB/complex_structures/6b4q.cif
  ./benchmark/dataset/CovPDB/complex_structures/6b4t.cif
  ./benchmark/dataset/CovPDB/complex_structures/6b56.cif
  ./benchmark/dataset/CovPDB/complex_structures/6bdp.cif
  ./benchmark/dataset/CovPDB/complex_structures/6bdq.cif
  ./benchmark/dataset/CovPDB/complex_structures/6bdr.cif
  ./benchmark/dataset/CovPDB/complex_structures/6bxj.cif
  ./benchmark/dataset/CovPDB/complex_structures/6da9.cif
  ./benchmark/dataset/CovPDB/complex_structures/6dwv.cif
  ./benchmark/dataset/CovPDB/complex_structures/6eac.cif
  ./benchmark/dataset/CovPDB/complex_structures/6eum.cif
  ./benchmark/dataset/CovPDB/complex_structures/6ew3.cif
  ./benchmark/dataset/CovPDB/complex_structures/6f0w.cif
  ./benchmark/dataset/CovPDB/complex_structures/6f2f.cif
  ./benchmark/dataset/CovPDB/complex_structures/6f2h.cif
  ./benchmark/dataset/CovPDB/complex_structures/6fp7.cif
  ./benchmark/dataset/CovPDB/complex_structures/6fp8.cif
  ./benchmark/dataset/CovPDB/complex_structures/6frn.cif
  ./benchmark/dataset/CovPDB/complex_structures/6fro.cif
  ./benchmark/dataset/CovPDB/complex_structures/6gsc.cif
  ./benchmark/dataset/CovPDB/complex_structures/6haa.cif
  ./benchmark/dataset/CovPDB/complex_structures/6mfe.cif
  ./benchmark/dataset/CovPDB/complex_structures/6mgy.cif
  ./benchmark/dataset/CovPDB/complex_structures/6mh0.cif
  ./benchmark/dataset/CovPDB/complex_structures/6mis.cif
  ./benchmark/dataset/CovPDB/complex_structures/6mjg.cif
  ./benchmark/dataset/CovPDB/complex_structures/pdb5yuv.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6a1f.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6a1g.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6b4q.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6b4t.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6b56.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6bdp.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6bdq.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6bdr.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6bxj.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6da9.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6dwv.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6eac.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6eum.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6ew3.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6f0w.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6f2f.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6f2h.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6fp7.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6fp8.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6frn.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6fro.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6gsc.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6haa.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6mfe.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6mgy.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6mh0.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6mis.ent
  ./benchmark/dataset/CovPDB/complex_structures/pdb6mjg.ent
  ./benchmark/dataset/CyanoOmicsDB/README.md
  ./benchmark/dataset/CyanoOmicsDB/md5sum.txt
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset.zip
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/assembly_data_report.jsonl
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/data_summary.tsv
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/dataset_catalog.json
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/gene_metadata.tsv
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic.1.bt2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic.2.bt2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic.3.bt2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic.4.bt2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic.fna
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic.rev.1.bt2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic.rev.2.bt2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic_hisat2.1.ht2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic_hisat2.2.ht2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic_hisat2.3.ht2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic_hisat2.4.ht2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic_hisat2.5.ht2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic_hisat2.6.ht2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic_hisat2.7.ht2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/GCF_000009725.1_ASM972v1_genomic_hisat2.8.ht2
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/cds_from_genomic.fna
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/demo_genomic.gff
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/genomic.gff
  ./benchmark/dataset/CyanoOmicsDB/ncbi_dataset/data/GCF_000009725.1/protein.faa
  ./benchmark/dataset/CyanoOm</observation>
<execute>
import os
import glob

# Search for TheMarker directory and files
print("Searching for TheMarker files...")

# Check in current directory structure
for root, dirs, files in os.walk("."):
    if "TheMarker" in root:
        print(f"Found TheMarker directory: {root}")
        for f in files:
            print(f"  File: {f}")

# Also search for files with PMID numbers and FDA
print("\nSearching for PMID and FDA files...")
for root, dirs, files in os.walk("."):
    for f in files:
        if "34903842" in f or "25135077" in f or "30289572" in f or "19435794" in f or "FDA" in f:
            print(f"Found: {os.path.join(root, f)}")

# Also search for ThMARs_TYPE.png
print("\nSearching for ThMARs_TYPE.png...")
for root, dirs, files in os.walk("."):
    for f in files:
        if "ThMARs_TYPE" in f:
            print(f"Found: {os.path.join(root, f)}")
</execute>
<observation>Searching for TheMarker files...
Found TheMarker directory: ./benchmark/dataset/TheMarker
  File: 19435794.pdf
  File: 25135077.pdf
  File: 30289572.pdf
  File: 34903842.pdf
  File: FDA.pdf
  File: ThMARs_TYPE.png
  File: biomarker.txt

Searching for PMID and FDA files...
Found: ./benchmark/dataset/TheMarker/19435794.pdf
Found: ./benchmark/dataset/TheMarker/25135077.pdf
Found: ./benchmark/dataset/TheMarker/30289572.pdf
Found: ./benchmark/dataset/TheMarker/34903842.pdf
Found: ./benchmark/dataset/TheMarker/FDA.pdf
Found: ./tmp/themarker_extract_1/19435794.txt
Found: ./tmp/themarker_extract_1/25135077.txt
Found: ./tmp/themarker_extract_1/30289572.txt
Found: ./tmp/themarker_extract_1/34903842.txt
Found: ./tmp/themarker_extract_1/FDA.txt

Searching for ThMARs_TYPE.png...
Found: ./benchmark/dataset/TheMarker/ThMARs_TYPE.png
</observation>
<execute>
from PIL import Image
import matplotlib.pyplot as plt
import os

# Define file paths
dataset_dir = "./benchmark/dataset/TheMarker/"
thmars_type_path = os.path.join(dataset_dir, "ThMARs_TYPE.png")

# Read and display the ThMARs_TYPE image
print("Reading ThMARs_TYPE.png to understand biomarker definitions...")
img = Image.open(thmars_type_path)
plt.figure(figsize=(15, 10))
plt.imshow(img)
plt.axis('off')
plt.title('Therapeutic Biomarker Types Definitions')
plt.savefig('/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/ThMARs_TYPE_preview.png', dpi=150, bbox_inches='tight')
plt.show()
print(f"Image size: {img.size}")
print(f"Image saved to temporary directory")
</execute>
<observation>Reading ThMARs_TYPE.png to understand biomarker definitions...
Image size: (1051, 560)
Image saved to temporary directory
</observation>
<execute>
import pytesseract
from PIL import Image

# Use OCR to extract text from the image
img = Image.open('./benchmark/dataset/TheMarker/ThMARs_TYPE.png')
ocr_text = pytesseract.image_to_string(img)
print("=== ThMARs_TYPE.png Content ===")
print(ocr_text)
print("================================")

# Save OCR result to file
with open('/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/ThMARs_TYPE.txt', 'w') as f:
    f.write(ocr_text)
</execute>
<observation>TesseractNotFoundError("tesseract is not installed or it's not in your PATH. See README file for more information.")</observation>
<execute>
import os

# Check the existing text files
tmp_dir = "./tmp/themarker_extract_1/"
print("Checking existing text files...")

for fname in os.listdir(tmp_dir):
    filepath = os.path.join(tmp_dir, fname)
    if fname.endswith('.txt'):
        with open(filepath, 'r') as f:
            content = f.read()
        print(f"\n=== {fname} ===")
        print(content[:2000] if len(content) > 2000 else content)
        print("..." if len(content) > 2000 else "")
</execute>
<observation>The output is too long to be added to context. Here are the first 10K characters...
Checking existing text files...

=== 19435794.txt ===
Cardiovascular, Pulmonary and Renal Pathology
Urinary Excretion of Liver Type Fatty Acid Binding
Protein Accurately Reflects the Degree of
Tubulointerstitial Damage
Takeshi Yokoyama,* Atsuko Kamijo-Ikemori,* †
Takeshi Sugaya,*‡ Seiko Hoshino,* Takashi Yasuda,*
and Kenjiro Kimura*
From the Division of Nephrology and Hypertension, * Department
of Internal Medicine, and the Department of Anatomy, †
St. Marianna University School of Medicine, Kanagawa;
and CMIC Co Ltd.,
‡ Tokyo, Japan
To investigate the relationship between liver-type
fatty acid-binding protein (L-FABP) , a biomarker of
chronic kidney disease , in the kidney and the degree
of tubulointerstitial damage , folic acid (FA)-induced
nephropathy was studied in a mouse model system.
As renal L-FABP is not expressed in wild-type mice ,
human L-FABP (hL-FABP) transgenic mice were used
in this study. hL-FABP is expressed in the renal prox-
imal tubules of the transgenic mice that were injected
intraperitoneally with FA in NaHCO
3 (the FA group)
or only NaHCO 3 (the control group) and oral saline
solution daily during the experimental period. The
FA group developed severe tubulointerstitial dam-
age with the infiltration of macrophages and the
deposition of type I collagen on days 3 and 7 and
recovered to the control level on day 14. The gene
and protein expression levels of hL-FABP in the
kidney were significantly enhanced on days 3 and
7. Urinary hL-FABP in the FA group was elevated on
days 3 and 7 and decreased to the control level on
day 14. The protein expression levels of hL-FABP in
both the kidney and urine significantly correlated
with the degree of tubulointerstitial damage , the in-
filtration of macrophages , and the deposition of type
I collagen. In conclusion , renal expression and uri-
nary excretion of hL-FABP significantly reflected the
severity of tubulointerstitial damage in FA-induced
nephropathy.
(Am J Pathol 2009, 174:2096 –2106; DOI:
10.2353/ajpath.2009.080780)
It is well known in the variety 
...

=== 25135077.txt ===
R E S E A R C H Open Access
Calprotectin (S100A8/9) as serum biomarker for
clinical response in proof-of-concept trials in axial
and peripheral spondyloarthritis
Maureen C Turina 1, Nataliya Yeremenko 1,2, Jacqueline E Paramarta 1, Leen De Rycke 1,3 and Dominique Baeten 1,2*
Abstract
Introduction: Biomarkers complementing clinical evaluations may help to reduce the length and size of
proof-of-concept (PoC) trials aimed to obtain quick “go/no go ” decisions in the clinical development of new
treatments. We aimed to identify and validate serum biomarkers with a high sensitivity to change upon effective
treatment in spondyloarthritis (SpA) PoC trials.
Methods: The candidate biomarkers high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), pentraxin-3
(PTX-3), alpha-2-macroglobulin (alpha-2-MG), matrix metalloproteinase-3 (MMP-3), calprotectin, and vascular
endothelial growth factor (VEGF) were determined by enzyme-linked immunosorbent assay (ELISA) in healthy
controls ( n = 20) and SpA patients before and after 2 weeks of infliximab ( n = 18) or placebo ( n = 19) treatment in
cohort 1. Clinical outcome was evaluated at week 12. Results were validated in ankylosing spondylitis (AS) with
infliximab (cohort 2, n = 21) and peripheral SpA with etanercept (cohort 3, n = 20).
Results: Serum levels of calprotectin, hs-CRP, PTX-3, VEGF (all P < 0.001) and MMP-3 ( P = 0.062), but not IL-6 and
alpha-2-MG, were increased in SpA versus healthy controls. Treatment with infliximab, but not placebo, significantly
decreased calprotectin ( P < 0.001) and hs-CRP ( P < 0.001) levels, with a similar trend for MMP-3 ( P = 0.063). The
standardized response mean (SRM), which reflects the ability to detect changes over time, was high for calprotectin
(−1.26), good for hs-CRP ( −0.96) and moderate for MMP-3 ( −0.52). Calprotectin and hs-CRP, but not MMP-3, were
good biomarkers for treatment response in axial and peripheral SpA as evaluated and confirmed in cohort 2 and
3 respective
...

=== 30289572.txt ===
ORIGINAL ARTICLE
Prediction of therapeutic response before and during i.v.
cyclophosphamide pulse therapy for interstitial lung disease
in systemic sclerosis: A longitudinal observational study
Hayakazu SUMIDA, Yoshihide ASANO, Zenshiro TAMAKI, Naohiko AOZASA,
Takashi TANIGUCHI, Tetsuo TOYAMA, Takehiro TAKAHASHI, Yohei ICHIMURA,
Shinji NODA, Kaname AKAMATA, Ryosuke SAIGUSA, Miki MIYAZAKI,
Yoshihiro KUWANO, Koichi YANABA, Ayumi YOSHIZAKI, Shinichi SATO
Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
ABSTRACT
There have been no established parameters to predict responsiveness to i.v. cyclophosphamide (IVCY) pulse ther-
apy in combination with corticosteroids in patients with interstitial lung disease (ILD) related to systemic sclerosis
(SSc). This retrospective study was conducted to determine predictive factors for efﬁcacy of IVCY at the time of
before and during the treatment. Thirty-two Japanese SSc patients, ever treated for ILD with IVCY in combination
with prednisolone, were analyzed retrospectively. We performed detailed time-course analyses of parameters
derived from blood samples and pulmonary function tests. With the exclusion of eight unclassiﬁed patients, 24
patients were classiﬁed into 14 good responders (GR) or 10 poor responders (PR) on the basis of changes in per-
cent predicted diffusing capacity for carbon monoxide (DLco). Pretreatment percent predicted DLco was signiﬁ-
cantly reduced in PR compared with GR. In addition, serum parameters such as Krebs von den Lungen-6 (KL-6),
surfactant protein D (SP-D) and C-reactive protein were signiﬁcantly higher in PR than in GR. Furthermore, our
time-course analyses revealed a transient increase in serum KL-6 levels with a peak at 3 months after the ﬁrst
infusion of cyclophosphamide, which showed no relation to therapeutic efﬁcacy. Moreover, continuously high
serum KL-6 levels ( >2000 U/mL) and rapid decrease in SP-D levels ( <200 ng/mL) during IVCY were remarkably
characte
...

=== 34903842.txt ===
ARTICLE
Clinical Studies
First-in-human phase 1 dose-escalation study of CAN04, a ﬁrst-
in-class interleukin-1 receptor accessory protein (IL1RAP)
antibody in patients with solid tumours
Debbie Robbrecht 1 ✉, Christiane Jungels 2, Morten Mau Sorensen 3, Iben Spanggaard 3, Ferry Eskens 1, Signe Ø Fretland 4,
Tormod Kyrre Guren 4, Philippe Aftimos 2, David Liberg 5, Christer Svedman 5, Lars Thorsson 5, Neeltje Steeghs 6 and Ahmad Awada 2
© The Author(s), under exclusive licence to Springer Nature Limited 2021
BACKGROUND: Interleukin-1 (IL-1) signalling is involved in various protumoural processes including proliferation, immune evasion,
metastasis and chemoresistance. CAN04 is a ﬁrst-in-class monoclonal antibody that binds IL-1 receptor accessory protein (IL1RAP),
required for IL-1 signalling. In this ﬁrst-in-human phase 1 study, we assessed safety, recommended phase 2 dose (RP2D),
pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of CAN04 monotherapy.
METHODS: Patients with advanced solid tumours known to express IL1RAP and refractory to standard treatments were enrolled in
a dose-escalation study with 5 dose levels (1.0 –10.0 mg/kg) of weekly CAN04.
RESULTS: Twenty-two patients were enrolled. Most common adverse events were infusion-related reactions (41%), fatigue (32%),
constipation (27%), diarrhoea (27%), decreased appetite (23%), nausea (23%) and vomiting (23%). One dose limiting toxicity was
reported. No maximum tolerated dose was identi ﬁed. Pharmacokinetics analyses indicate higher exposures and slower elimination
with increasing doses. Decreases in serum IL-6 and CRP were observed in most patients. Twenty-one patients were evaluable for
response, 43% had stable disease per immune-related response criteria with no partial/complete responses.
CONCLUSIONS: The IL1RAP targeting antibody CAN04 can be safely administered to patients up to 10.0 mg/kg weekly, which was
deﬁned as the RP2D. Serum biomarkers supported target engagement and IL-1 pa
...

=== FDA.txt ===
Page 1 of 17  
HIGHLIGHTS OF PRESCRIBING INFORMATION 
These highlights do not include all the information needed to use 
AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, 
Adjuvanted) safely and effectively. See full prescribing information for 
AUDENZ. 
 
AUDENZ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) 
injectable emulsion for intramuscular use 
 
Initial U.S. Approval: 2020 
-----------------------------INDICATIONS AND USAGE-------------------------- 
AUDENZ is an inactivated vaccine indicated for active immunization for the 
prevention of disease caused by the influenza A virus H5N1 subtype 
contained in the vaccine. AUDENZ is approved for use in persons 6 months 
of age and older at increased risk of exposure to the influenza A virus H5N1 
subtype contained in the vaccine. (1) 
------------------------DOSAGE AND ADMINISTRATION---------------------- 
For intramuscular injection only 
Administer two doses (0.5 mL each) 21 days apart. (2) 
----------------------DOSAGE FORMS AND STRENGTHS--------------------- 
Injectable emulsion is supplied in two presentations: 
• 0.5 mL single-dose pre-filled syringe. (3, 11) 
• 5 mL multi-dose vial containing 10 doses (each dose is 0.5 mL). 
(3, 11) 
 
-----------------------------CONTRAINDICATIONS-------------------------------- 
History of a severe allergic reaction (e.g., anaphylaxis) to any component of 
the vaccine, or after a previous dose of an influenza vaccine. (4, 11) 
-------------------------WARNINGS AND PRECAUTIONS---------------------- 
• Hypersensitivity reactions can occur. Appropriate medical treatment and 
supervision must be available to manage possible anaphylactic reactions 
following administration of the vaccine. (5.1) 
• If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a 
prior influenza vaccine, the decision to give AUDEN</observation>
<execute>
# Read the biomarker.txt file which might have type definitions
dataset_dir = "./benchmark/dataset/TheMarker/"
with open(os.path.join(dataset_dir, "biomarker.txt"), 'r') as f:
    biomarker_content = f.read()
print("=== biomarker.txt content ===")
print(biomarker_content)
</execute>
<observation>NameError("name 'os' is not defined")</observation>
<execute>
import os

# Read the biomarker.txt file which might have type definitions
dataset_dir = "./benchmark/dataset/TheMarker/"
with open(os.path.join(dataset_dir, "biomarker.txt"), 'r') as f:
    biomarker_content = f.read()
print("=== biomarker.txt content ===")
print(biomarker_content)
</execute>
<observation>=== biomarker.txt content ===
Biomarker ID	Biomarker Name	Gene Name	Synonyms	Biomarker Class	Function
B07XCZ	Laminin subunit alpha-3	LAMA3; LAMNA	Laminin subunit alpha 3; Epiligrin 170 kDa subunit; E170; Epiligrin subunit alpha; Kalinin subunit alpha; Laminin-5 subunit alpha; Laminin-6 subunit alpha; Laminin-7 subunit alpha; Nicein subunit alpha	Protein	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. Laminin-5 is thought to be involved in cell adhesion via integrin alpha-3/beta-1 in focal adhesion and integrin alpha-6/beta-4 in hemidesmosomes, signal transduction via tyrosine phosphorylation of pp125-FAK and p80, differentiation of keratinocytes.
B36BFV	IL2 mRNA	IL2	Interleukin-2 mRNA; IL-2 mRNA; T-cell growth factor mRNA; TCGF mRNA	mRNA	Cytokine produced by activated CD4-positive helper T-cells and to a lesser extend activated CD8-positive T-cells and natural killer cells that plays pivotal roles in the immune response and tolerance. Binds to a receptor complex composed of either the high-affinity trimeric IL-2R or the low-affinity dimeric IL-2R. Interaction with the receptor leads to oligomerization and conformation changes in the IL-2R subunits resulting in downstream signaling starting with phosphorylation of JAK1 and JAK3. In turn, JAK1 and JAK3 phosphorylate the receptor to form a docking site leading to the phosphorylation of several substrates including STAT5. This process leads to activation of several pathways including STAT, phosphoinositide-3-kinase/PI3K and mitogen-activated protein kinase/MAPK pathways. Functions as a T-cell growth factor and can increase NK-cell cytolytic activity as well. Promotes strong proliferation of activated B-cells and subsequently immunoglobulin production. Plays a pivotal role in regulating the adaptive immune system by controlling the survival and proliferation of regulatory T-cells, which are required for the maintenance of immune tolerance. Moreover, participates in the differentiation and homeostasis of effector T-cell subsets, including Th1, Th2, Th17 as well as memory CD8-positive T-cells.
B12RGS	Clusterin	CLU; APOJ; CLI; KUB1; AAG4	Ku70-binding protein 1; KUB1; Complement-associated protein SP-40,40; Complement cytolysis inhibitor; CLI; Apolipoprotein J; ApoJ; Apo-J ; Aging-associated gene 4 protein; AAG4	Protein	Functions as extracellular chaperone that prevents aggregation of non native proteins. Prevents stress-induced aggregation of blood plasma proteins. Inhibits formation of amyloid fibrils by APP, APOC2, B2M, CALCA, CSN3, SNCA and aggregation-prone LYZ variants. Does not require ATP. Maintains partially unfolded proteins in a state appropriate for subsequent refolding by other chaperones, such as HSPA8/HSC70. Does not refold proteins by itself. Binding to cell surface receptors triggers internalization of the chaperone-client complex and subsequent lysosomal or proteasomal degradation. Protects cells against apoptosis and against cytolysis by complement. Intracellular forms interact with ubiquitin and SCF E3 ubiquitin-protein ligase complexes and promote the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes proteasomal degradation of COMMD1 and IKBKB. Modulates NF-kappa-B transcriptional activity. A mitochondrial form suppresses BAX-dependent release of cytochrome c into the cytoplasm and inhibit apoptosis. Plays a role in the regulation of cell proliferation. An intracellular form suppresses stress-induced apoptosis by stabilizing mitochondrial membrane integrity through interaction with HSPA5. Secreted form does not affect caspase or BAX-mediated intrinsic apoptosis and TNF-induced NF-kappa-B-activity. Secreted form act as an important modulator during neuronal differentiation through interaction with STMN3. Plays a role in the clearance of immune complexes that arise during cell injury. Does not affect caspase or BAX-mediated intrinsic apoptosis and TNF-induced NF-kappa-B-activity. Does not affect caspase or BAX-mediated intrinsic apoptosis and TNF-induced NF-kappa-B-activity. Promotes cell death through interaction with BCL2L1 that releases and activates BAX.
B1W4DT	Urokinase plasminogen activator surface receptor	PLAUR; MO3; UPAR	Urokinase-type plasminogen activator receptor; Urokinase plasminogen activator receptor; Monocyte activation antigenMo3; CD87 antigen; CD87	Protein	Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.

</observation>
<execute>
import pdfplumber
import os

# Define paths
dataset_dir = "./benchmark/dataset/TheMarker/"
pmid_files = ["19435794.pdf", "25135077.pdf", "30289572.pdf", "34903842.pdf", "FDA.pdf"]

# Extract text from each PDF and save
for pmid_file in pmid_files:
    pmid = pmid_file.replace('.pdf', '')
    pdf_path = os.path.join(dataset_dir, pmid_file)
    
    print(f"\n=== Extracting {pmid_file} ===")
    text_content = []
    
    try:
        with pdfplumber.open(pdf_path) as pdf:
            for i, page in enumerate(pdf.pages):
                text = page.extract_text()
                if text:
                    text_content.append(f"--- Page {i+1} ---\n{text}")
        
        full_text = "\n\n".join(text_content)
        print(f"Extracted {len(text_content)} pages, {len(full_text)} characters")
        
        # Save to intermediate directory
        output_path = f"/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/{pmid}.txt"
        with open(output_path, 'w', encoding='utf-8') as f:
            f.write(full_text)
        print(f"Saved to: {output_path}")
        
        # Print first 2000 chars for preview
        print("\nPreview:")
        print(full_text[:2000])
        print("..." if len(full_text) > 2000 else "")
        
    except Exception as e:
        print(f"Error: {e}")
</execute>
<observation>The output is too long to be added to context. Here are the first 10K characters...

=== Extracting 19435794.pdf ===
Extracted 11 pages, 48838 characters
Saved to: /root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/19435794.txt

Preview:
--- Page 1 ---
TheAmericanJournalofPathology,Vol.174,No.6,June2009
Copyright©AmericanSocietyforInvestigativePathology
DOI:10.2353/ajpath.2009.080780
Cardiovascular, Pulmonary and Renal Pathology
Urinary Excretion of Liver Type Fatty Acid Binding
Protein Accurately Reflects the Degree of
Tubulointerstitial Damage
Takeshi Yokoyama,* Atsuko Kamijo-Ikemori,*† functionandtheameliorationoftubulointerstitialdamage
TakeshiSugaya,*‡SeikoHoshino,*TakashiYasuda,* retards the progression of kidney disease.1–3 Therefore,
andKenjiroKimura* a biomarker that accurately reflects the degree of the
tubulointerstitial damage should be a useful clinical tool
FromtheDivisionofNephrologyandHypertension,*Department
tomonitorkidneydiseaseanditstreatments.
ofInternalMedicine,andtheDepartmentofAnatomy,†
Recently,urinaryexcretionofliver-typefattyacidbind-
St.MariannaUniversitySchoolofMedicine,Kanagawa;
ingprotein(L-FABP)hasbeenclinicallyrecognizedasa
andCMICCoLtd.,‡Tokyo,Japan
useful biomarker for monitoring chronic kidney disease
and early detection of acute kidney injury.4,5 L-FABP is
expressed in the human proximal tubules of the kid-
ney.6,7 human L-FABP (hL-FABP) binds fatty acids and
To investigate the relationship between liver-type
transports them to mitochondria or peroxisomes, where
fatty acid-binding protein (L-FABP), a biomarker of fattyacidsare(cid:1)-oxidized,andparticipatesinintracellular
chronickidneydisease,inthekidneyandthedegree
fatty acid homeostasis.8,9 Some experimental studies of
of tubulointerstitial damage, folic acid (FA)-induced
animal models of kidney disease with tubulointerstitial
nephropathy was studied in a mouse model system.
damage revealed that renal hL-FABP was up-regulated
As renal L-FABP is not expressed in wild-type mice,
and urinary excretion of hL-FABP was increased.4,10–12
humanL-FABP(hL-FABP)transgenicmicewereused
From our studies, we considered that the increase in
inthisstudy.hL-FABPisexpressedintherenalprox-
urinary hL-FABP is caused by the increas
...

=== Extracting 25135077.pdf ===
Extracted 9 pages, 41941 characters
Saved to: /root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/25135077.txt

Preview:
--- Page 1 ---
Turinaetal.ArthritisResearch&Therapy2014,16:413
http://arthritis-research.com/content/16/4/413
RESEARCH Open Access
Calprotectin (S100A8/9) as serum biomarker for
clinical response in proof-of-concept trials in axial
and peripheral spondyloarthritis
Maureen C Turina1, Nataliya Yeremenko1,2, Jacqueline E Paramarta1, Leen De Rycke1,3 and Dominique Baeten1,2*
Abstract
Introduction: Biomarkers complementing clinical evaluations may help to reduce the length and size of
proof-of-concept (PoC) trials aimed to obtain quick “go/no go” decisions intheclinical development ofnew
treatments. We aimed to identify and validate serum biomarkers witha highsensitivity to change upon effective
treatment inspondyloarthritis (SpA) PoC trials.
Methods: The candidate biomarkers high-sensitivity C-reactive protein (hs-CRP),interleukin-6 (IL-6), pentraxin-3
(PTX-3), alpha-2-macroglobulin (alpha-2-MG),matrix metalloproteinase-3 (MMP-3), calprotectin, and vascular
endothelial growth factor (VEGF) were determinedby enzyme-linked immunosorbent assay (ELISA) inhealthy
controls (n=20) and SpA patients before and after 2weeks of infliximab (n=18) or placebo (n=19) treatment in
cohort 1. Clinical outcome was evaluated atweek 12.Resultswere validatedin ankylosing spondylitis (AS) with
infliximab (cohort 2, n=21) and peripheral SpA with etanercept (cohort 3, n=20).
Results: Serum levels of calprotectin, hs-CRP,PTX-3, VEGF (all P<0.001) and MMP-3 (P=0.062), but not IL-6 and
alpha-2-MG, were increased inSpA versus healthy controls. Treatment with infliximab,but not placebo, significantly
decreased calprotectin (P<0.001)and hs-CRP(P<0.001)levels, witha similartrend for MMP-3 (P=0.063). The
standardized response mean(SRM),which reflects theability to detect changes over time, was high for calprotectin
(−1.26),good for hs-CRP (−0.96) and moderate for MMP-3 (−0.52). Calprotectin and hs-CRP, but not MMP-3, were
goodbiomarkers for treatment response in axial and peripheral SpA as evaluated an
...

=== Extracting 30289572.pdf ===
Extracted 9 pages, 39768 characters
Saved to: /root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/30289572.txt

Preview:
--- Page 1 ---
doi:10.1111/1346-8138.14669 Journal of Dermatology2018; 45:1425–1433
ORIGINAL ARTICLE
Prediction of therapeutic response before and during i.v.
cyclophosphamide pulse therapy for interstitial lung disease
in systemic sclerosis: A longitudinal observational study
Hayakazu SUMIDA, Yoshihide ASANO, Zenshiro TAMAKI, Naohiko AOZASA,
Takashi TANIGUCHI, Tetsuo TOYAMA, Takehiro TAKAHASHI, Yohei ICHIMURA,
Shinji NODA, Kaname AKAMATA, Ryosuke SAIGUSA, Miki MIYAZAKI,
Yoshihiro KUWANO, Koichi YANABA, Ayumi YOSHIZAKI, Shinichi SATO
Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
ABSTRACT
Therehavebeennoestablishedparameterstopredictresponsivenesstoi.v.cyclophosphamide(IVCY)pulsether-
apyincombinationwithcorticosteroidsinpatientswithinterstitiallungdisease(ILD)relatedtosystemicsclerosis
(SSc). This retrospective study was conducted to determine predictive factors for efficacy of IVCY at the time of
before and during the treatment. Thirty-two Japanese SScpatients, ever treatedfor ILD withIVCY incombination
with prednisolone, were analyzed retrospectively. We performed detailed time-course analyses of parameters
derived from blood samples and pulmonary function tests. With the exclusion of eight unclassified patients, 24
patients were classified into 14 goodresponders (GR) or10poor responders(PR) onthe basis ofchanges inper-
cent predicted diffusing capacity for carbon monoxide (DLco). Pretreatment percent predicted DLco was signifi-
cantly reduced in PR compared with GR. In addition, serum parameters such as Krebs von den Lungen-6 (KL-6),
surfactant protein D (SP-D) and C-reactive protein were significantly higher in PR than in GR. Furthermore, our
time-course analyses revealed a transient increase in serum KL-6 levels with a peak at 3 months after the first
infusion of cyclophosphamide, which showed no relation to therapeutic efficacy. Moreover, continuously high
serum KL-6 levels (>2000 U/mL) and rapid decrease in SP-D levels 
...

=== Extracting 34903842.pdf ===
Extracted 8 pages, 44025 characters
Saved to: /root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/34903842.txt

Preview:
--- Page 1 ---
British Journal of Cancer
www.nature.com/bjc
ARTICLE
Clinical Studies
fi
First-in-human phase 1 dose-escalation study of CAN04, a rst-
in-class interleukin-1 receptor accessory protein (IL1RAP)
antibody in patients with solid tumours
✉
DebbieRobbrecht 1 , Christiane Jungels2, Morten MauSorensen 3, IbenSpanggaard3, Ferry Eskens1, Signe ØFretland4,
Tormod KyrreGuren 4, PhilippeAftimos2, David Liberg5,Christer Svedman5, Lars Thorsson5, Neeltje Steeghs6 and AhmadAwada2
©TheAuthor(s),underexclusivelicencetoSpringerNatureLimited2021
BACKGROUND:Interleukin-1(IL-1)signallingisinvolvedinvariousprotumouralprocessesincludingproliferation,immuneevasion,
metastasisandchemoresistance.CAN04isafirst-in-classmonoclonalantibodythatbindsIL-1receptoraccessoryprotein(IL1RAP),
required for IL-1signalling. Inthis first-in-human phase1study, weassessed safety,recommended phase2dose (RP2D),
pharmacokinetics, pharmacodynamics and preliminary anti-tumouractivity of CAN04 monotherapy.
METHODS:PatientswithadvancedsolidtumoursknowntoexpressIL1RAPandrefractorytostandardtreatmentswereenrolledin
a dose-escalation study with 5dose levels (1.0–10.0mg/kg)of weeklyCAN04.
RESULTS:Twenty-twopatientswereenrolled.Mostcommonadverseeventswereinfusion-relatedreactions(41%),fatigue(32%),
constipation (27%),diarrhoea(27%),decreasedappetite (23%),nausea(23%)andvomiting(23%).Onedose limitingtoxicity was
reported.Nomaximumtolerateddosewasidentified.Pharmacokineticsanalysesindicatehigherexposuresandslowerelimination
withincreasingdoses.DecreasesinserumIL-6andCRPwereobservedinmostpatients.Twenty-onepatientswereevaluablefor
response, 43%had stabledisease per immune-relatedresponse criteria with no partial/complete responses.
CONCLUSIONS:TheIL1RAPtargetingantibodyCAN04canbesafelyadministeredtopatientsupto10.0mg/kgweekly,whichwas
definedastheRP2D. Serumbiomarkers supported target engagement andIL-1 pathway inhibition.
CLINICAL TRIAL REGISTRATION: NCT03267316.
British Journalof Cancer (2022)126:1010–1017;
...

=== Extracting FDA.pdf ===
Extracted 17 pages, 41201 characters
Saved to: /root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/FDA.txt

Preview:
--- Page 1 ---
HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------WARNINGS AND PRECAUTIONS----------------------
These highlights do not include all the information needed to use • Hypersensitivity reactions can occur. Appropriate medical treatment and
AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, supervision must be available to manage possible anaphylactic reactions
Adjuvanted) safely and effectively. See full prescribing information for following administration of the vaccine. (5.1)
AUDENZ. • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a
prior influenza vaccine, the decision to give AUDENZ should be based on
AUDENZ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) careful consideration of potential benefits and risks. (5.2)
injectable emulsion for intramuscular use
------------------------------ADVERSE REACTIONS-------------------------------
Initial U.S. Approval: 2020 • In adults 18 through 64 years of age, the most common (≥ 10%) solicited
local and systemic reactions reported in clinical trials were injection site
-----------------------------INDICATIONS AND USAGE----------</observation>
<execute>
# Read full FDA document to check for biomarker definitions
with open('/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/FDA.txt', 'r') as f:
    fda_content = f.read()
    
print("=== Full FDA Document ===")
print(fda_content)
</execute>
<observation>The output is too long to be added to context. Here are the first 10K characters...
=== Full FDA Document ===
--- Page 1 ---
HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------WARNINGS AND PRECAUTIONS----------------------
These highlights do not include all the information needed to use • Hypersensitivity reactions can occur. Appropriate medical treatment and
AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, supervision must be available to manage possible anaphylactic reactions
Adjuvanted) safely and effectively. See full prescribing information for following administration of the vaccine. (5.1)
AUDENZ. • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a
prior influenza vaccine, the decision to give AUDENZ should be based on
AUDENZ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) careful consideration of potential benefits and risks. (5.2)
injectable emulsion for intramuscular use
------------------------------ADVERSE REACTIONS-------------------------------
Initial U.S. Approval: 2020 • In adults 18 through 64 years of age, the most common (≥ 10%) solicited
local and systemic reactions reported in clinical trials were injection site
-----------------------------INDICATIONS AND USAGE-------------------------- pain (64%), fatigue (25%), headache (25%), malaise (22%), myalgia
AUDENZ is an inactivated vaccine indicated for active immunization for the (14%), arthralgia (10%), and nausea (10%). (6.1)
prevention of disease caused by the influenza A virus H5N1 subtype • In adults 65 years of age and older, the most common (≥ 10%) solicited
contained in the vaccine. AUDENZ is approved for use in persons 6 months local and systemic reactions reported in clinical trials were injection site
of age and older at increased risk of exposure to the influenza A virus H5N1 pain (36%), fatigue (20%), malaise (16%), headache (16%), and arthralgia
subtype contained in the vaccine. (1) (10%). (6.1)
• In infants and children, 6 months through 5 years of age, the most common
------------------------DOSAGE AND ADMINISTRATION----------------------
(≥ 10%) solicited local and systemic reactions reported in clinical trials
For intramuscular injection only
were tenderness (56%), irritability (30%), sleepiness (25%), change in
Administer two doses (0.5 mL each) 21 days apart. (2)
eating habits (18%), and fever (16%). (6.1)
----------------------DOSAGE FORMS AND STRENGTHS--------------------- • In children 6 through 17 years of age, the most common (≥ 10%) solicited
Injectable emulsion is supplied in two presentations: local and systemic reactions reported in clinical trials were injection site
• 0.5 mL single-dose pre-filled syringe. (3, 11) pain (68%), myalgia (30%), fatigue (27%), malaise (25%), headache
• 5 mL multi-dose vial containing 10 doses (each dose is 0.5 mL). (22%), loss of appetite (14%), nausea (13%), and arthralgia (13%). (6.1)
(3, 11)
To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at
1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.
-----------------------------CONTRAINDICATIONS--------------------------------
See 17 for PATIENT COUNSELING INFORMATION.
History of a severe allergic reaction (e.g., anaphylaxis) to any component of
the vaccine, or after a previous dose of an influenza vaccine. (4, 11)
Revised: [10]/ [2023]
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
Dose and Schedule
Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Guillain-Barré Syndrome
Limitations of Vaccine Effectiveness
6 ADVERSE REACTIONS
Clinical Trials Experience
Postmarketing Experience
7 DRUG INTERACTIONS
Concomitant Vaccine Administrations
Concurrent Use with Immunosuppressive Therapies
8 USE IN SPECIFIC POPULATIONS
Pregnancy
Lactation
Pediatric Use
Geriatric Use
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
Mechanism of Action
13 NONCLINICAL TOXICOLOGY
Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
Immunological Evaluation
15 REFERENCES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
*Sections or subsections omitted from the full prescribing information are not
listed.
Page 1 of 17

--- Page 2 ---
FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
AUDENZTM is an inactivated vaccine indicated for active immunization for the prevention of
disease caused by the influenza A virus H5N1 subtype contained in the vaccine. AUDENZ is
approved for use in persons 6 months of age and older at increased risk of exposure to the
influenza A H5N1 virus subtype contained in the vaccine.
2 DOSAGE AND ADMINISTRATION
For intramuscular injection only
Dose and Schedule
Administer two doses of AUDENZ (0.5 mL each), 21 days apart.
Administration
Shake the syringe gently before use and shake the multi-dose vial gently each time before
withdrawing a dose of vaccine. Between multi-dose vial uses, return to the recommended storage
conditions of 2º to 8ºC (36º to 46ºF). AUDENZ has a milky-white appearance. Parenteral drug
products should be inspected visually for particulate matter and discoloration prior to
administration whenever solution and container permit [see Description (11)]. If either condition
exists, AUDENZ should not be administered.
The vaccine should be administered by intramuscular injection. Do not inject the vaccine in the
gluteal region or areas where there may be a major nerve trunk. For persons 12 months of age
and over, the preferred injection site is the deltoid muscle of the upper arm; for those 6 months
through 11 months of age, the preferred injection site is the anterolateral thigh.
3 DOSAGE FORMS AND STRENGTHS
AUDENZ is an injectable emulsion for intramuscular use supplied in two presentations:
• 0.5 mL single-dose pre-filled syringe
• 5 mL multi-dose vial containing 10 doses (each dose is 0.5 mL).
4 CONTRAINDICATIONS
Do not administer AUDENZ to anyone with a history of a severe allergic reaction (e.g.,
anaphylaxis) to any component of the vaccine [see Description (11)] or after a previous dose of
an influenza vaccine.
Page 2 of 17

--- Page 3 ---
5 WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Appropriate medical treatment and supervision must be available to manage possible severe
allergic reactions (e.g., anaphylaxis) following administration of the vaccine.
Guillain-Barré Syndrome
If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of receipt of prior influenza
vaccine, the decision to give AUDENZ should be based on careful consideration of the potential
benefits and risks. The 1976 swine influenza vaccine was associated with an elevated risk of
GBS. Evidence for a causal relationship of GBS with other influenza vaccines is inconclusive; if
an excess risk exists, it is probably slightly more than 1 additional case per 1 million persons
vaccinated.1
Limitations of Vaccine Effectiveness
Vaccination with AUDENZ may not protect all recipients.
Immunocompromised persons, including those receiving immunosuppressive therapy, may have
a diminished immune response to AUDENZ.
6 ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical
trials of another vaccine and may not reflect the rates observed in practice. It is possible that
broad use of AUDENZ could reveal adverse reactions not observed in clinical trials.
In adults 18 through 64 years of age, the most common (≥ 10%) solicited local and systemic
reactions reported in clinical trials were injection site pain (64%), fatigue (25%), headache
(25%), malaise (22%), myalgia (14%), arthralgia (10%) and nausea (10%).
In adults 65 years of age and older, the most common (≥ 10%) solicited local and systemic
reactions reported in clinical trials were injection site pain (36%), fatigue (20%), malaise (16%),
headache (16%), and arthralgia (10%).
In infants and children, 6 months through 5 years of age, the most common (≥ 10%) solicited
local and systemic reactions reported in clinical trials were tenderness (56%), irritability (30%),
sleepiness (25%), change in eating habits (18%), and fever (16%).
In children 6 years through 17 years of age, the most common (≥ 10%) solicited local and
systemic reactions reported in clinical trials were injection site pain (68%), myalgia (30%),
fatigue (27%), malaise (25%), headache (22%), loss of appetite (14%), nausea (13%), and
arthralgia (13%).
Page 3 of 17

--- Page 4 ---
Adults 18 years of age and older:
Clinical safety data for AUDENZ in adults (18 years of age and older) have been collected from
three studies: Study 1 in adults 18 through 64 years of age (NCT01776541); Study 2 in adults 65
years of age and older (NCT01766921), and Study 3, a placebo-controlled trial in adults 18 years
of age and older (NCT02839330). Subjects in all studies received 2 doses of AUDENZ,
administered intramuscularly 21 days apart. In all three studies, solicited local and systemic
adverse reactions were collected for 7 days and unsolicited adverse events were collected for 21
days following each vaccination. Serious adverse events (SAEs), adverse events of special
interest (AESIs) (prospectively defined events representing potential immune-mediated
conditions), new onset of chronic diseases (NOCDs) (adverse events leading to a new diagnosis
of a chronic medical condition), and medically-attended adverse events (MAAEs) (leading to an
unscheduled healthcare visit) were collected for one year following the final vaccination in each
subject. The safety population includes 3,579 subjects who received at least one dose of
AUDENZ. Of these, 1,683 were adults 18 through 64 years of age and 1,896 were adults 65 years
of age and older.
Study 3 was a randomized, observer-blind, multicenter, controlled study conducted in the US, in
adults 18 years of age and older. Subjects were randomized in a 3:1 ratio to receive two doses of
either AUDENZ or saline placebo, 21 days apart. In</observation>
<execute>
import os
import re

tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/"

# Define biomarker types based on standard definitions
"""
Biomarker Types:
1. Pharmacodynamic biomarker (PDY) - Indicates drug effect on target/pathway
2. Safety biomarker (SAF) - Indicates toxicity/adverse effects  
3. Monitoring biomarker (MOI) - Tracks disease progression/response to treatment
4. Predictive biomarker (PRD) - Predicts treatment response before treatment
5. Surrogate endpoint (SUR) - Substitute for clinical endpoint
"""

# Search for CRP/PTX1/PTX-1 in all papers
files = ["19435794.txt", "25135077.txt", "30289572.txt", "34903842.txt", "FDA.txt"]

for fname in files:
    filepath = os.path.join(tmp_dir, fname)
    with open(filepath, 'r') as f:
        content = f.read()
    
    print(f"\n=== {fname} - CRP/PTX1 occurrences ===")
    
    # Search for CRP, PTX1, PTX-1, PTX3, pentraxin
    patterns = [r'CRP', r'PTX1', r'PTX-1', r'PTX3', r'PTX-3', r'pentraxin', r'Pentraxin']
    for pattern in patterns:
        matches = re.finditer(pattern, content, re.IGNORECASE)
        for match in matches:
            # Get context around match
            start = max(0, match.start() - 100)
            end = min(len(content), match.end() + 100)
            context = content[start:end]
            print(f"  {pattern}: ...{context}...")
</execute>
<observation>The output is too long to be added to context. Here are the first 10K characters...

=== 19435794.txt - CRP/PTX1 occurrences ===

=== 25135077.txt - CRP/PTX1 occurrences ===
  CRP: ...thritis (SpA) PoC trials.
Methods: The candidate biomarkers high-sensitivity C-reactive protein (hs-CRP),interleukin-6 (IL-6), pentraxin-3
(PTX-3), alpha-2-macroglobulin (alpha-2-MG),matrix metalloprotei...
  CRP: ...=21) and peripheral SpA with etanercept (cohort 3, n=20).
Results: Serum levels of calprotectin, hs-CRP,PTX-3, VEGF (all P<0.001) and MMP-3 (P=0.062), but not IL-6 and
alpha-2-MG, were increased inSpA ve...
  CRP: ...ls. Treatment with infliximab,but not placebo, significantly
decreased calprotectin (P<0.001)and hs-CRP(P<0.001)levels, witha similartrend for MMP-3 (P=0.063). The
standardized response mean(SRM),which r...
  CRP: ...hich reflects theability to detect changes over time, was high for calprotectin
(−1.26),good for hs-CRP (−0.96) and moderate for MMP-3 (−0.52). Calprotectin and hs-CRP, but not MMP-3, were
goodbiomarkers...
  CRP: ...or calprotectin
(−1.26),good for hs-CRP (−0.96) and moderate for MMP-3 (−0.52). Calprotectin and hs-CRP, but not MMP-3, were
goodbiomarkers for treatment response in axial and peripheral SpA as evaluated...
  CRP: ...ipheral SpA as evaluated and confirmedin cohort 2and
3respectively.
Conclusions: Calprotectinand hs-CRP are good serum biomarkers with high sensitivity to change upon effective
treatment atthe group leve...
  CRP: ...ment response in SpA. C- [1]. Cohort 2 consisted of 21 patients with AS according
reactive protein (CRP) is known to be elevated in active tothemodifiedNewYorkcriteria,treatedwithinfliximab
disease and t...
  CRP: ...onsisted of 20 patients with peripheral SpA treated with
two thirds of the SpA patients have normal CRP levels etanercept (25 mg subcutaneously bi-weekly) [31]. None
[11-14]. IL-6 is the main driver of C...
  CRP: ...P levels etanercept (25 mg subcutaneously bi-weekly) [31]. None
[11-14]. IL-6 is the main driver of CRP; serum IL-6 levels of the patients had been previously treated with a TNF
are significantly increas...
  CRP: ...esponse after TNF blockade [15,16]. Al- the first two cohorts, and at baseline and week 4 for
thoughCRPbelongstotheshortpentraxins,thepentraxin cohort 3. The complete description of these cohorts and
fam...
  CRP: ...proposed as biomarkers of [1,30,31].
inflammation [17]. Alpha-2-macroglobulin (alpha-2-MG)
isanotherCRP-independentacute-phaseresponseprotein
Serumbiomarkers
thatisusedasserumbiomarker[18].
Wedeterminedt...
  CRP: ...ted by the manufacturers:
tial biomarkers have been identified based on their
high-sensitivity (hs)-CRP (Research & Diagnostic Systems,
involvement in the immunopathology of SpA. Matrix
Inc. Minneapolis)...
  CRP: ...tients for calprotectin, 82% for VEGF,
markers of interest; it was not the aim to identify 81%forhs-CRP,74%forMMP-3and59%forPTX-3.
markers with a high diagnostic discriminative capacity
between SpA and H...
  CRP: ...
markers with a high diagnostic discriminative capacity
between SpA and HCs. The serum levels of hs-CRP Short-termmodulationofserumbiomarkersbyinfliximab
(16.44±2.36 μg/ml versus 0.84±0.27 μg/ml; P <0.00...
  CRP: ...Independentsamples
t-testswereperformed.Dataarerepresentedasmean(standarderrorofthemean).*P<0.05.hs-CRP,high-sensitivityC-reactiveprotein;IL-6,
interleukin-6;PTX-3,pentraxin-3;alpha-2-MG,alpha-2-macroglo...
  CRP: ...tent/16/4/413
therapy. We previously reported that both arms of this decrease in serum levels of hs-CRP (P <0.001), IL-6
cohort were well-randomized for disease activity (as (P=0.047),andcalprotectin(P<0...
  CRP: ...
(Figure 2). In the placebo group, none of the serum Asthepreviousanalysesidentifiedcalprotectin,hs-CRP,IL-
biomarkers changed significantly between baseline and 6 and MMP-3 as the most promising biomark...
  CRP: ...hritis(SpA).Pairedt-testswereperformed.Dataarerepresentedasmean(standarderrorofthemean),
*P<0.05.hs-CRP,high-sensitivityC-reactiveprotein;IL-6,interleukin-6;PTX-3,pentraxin-3;alpha-2-MG,alpha-2-macroglob...
  CRP: ...mab group was −1.26 for calprotectin, −0.96 for andPsA.Toascertainthatthebiomarkerfindingsarenot
hs-CRP, −0.56 for IL-6, and −0.52 for MMP-3. In com- biased by the SpA subtype and that the data can be ex...
  CRP: ...group was −0.20 for trapolated to more homogenous SpA study populations,
calprotectin, −0.13 for hs-CRP, −0.05 for IL-6, and 0.23 weperformedtwoadditionalsetsofanalysis.First,werea-
for MMP-3. Thus, the ...
  CRP: ...bo) were −1.06 for calprotec- (n=8 in the infliximab group and n=9 in the placebo
tin, −0.83 for hs-CRP, −0.51 for IL-6, and −0.75 for group)andPsA(n=8intheinfliximabgroupandn=9in
MMP-3. As calprotectin ...
  CRP: ... for IL-6, and −0.75 for group)andPsA(n=8intheinfliximabgroupandn=9in
MMP-3. As calprotectin and hs-CRP correlated moder- the placebo group). In the AS group, only hs-CRP (P=
ately (r=0.648), we next aim...
  CRP: ...in
MMP-3. As calprotectin and hs-CRP correlated moder- the placebo group). In the AS group, only hs-CRP (P=
ately (r=0.648), we next aimed to confirm that an early 0.006) and calprotectin (P=0.028) decre...
  CRP: ...rly 0.006) and calprotectin (P=0.028) decreased significantly
changeincalprotectinlevelsissuperiortoCRPasabio- aftertwoweeksofinfliximabtreatment(Figure3A).De-
marker of clinically effective treatment by...
  CRP: ...e SRM was −0.98 for calprotectin
cebotreatmentusingchangesincalprotectinlevelsover and −1.39 for hs-CRP. For PsA patients, only calprotec-
two weeks as the outcome parameter with a power of tin (P=0.003)...
  CRP: ...nfliximab treatment, with a similar but non-significant
patients per group. A similar analysis with CRP would trend for hs-CRP (P=0.071) (Figure 3B). None of the
require 24 patients per group. Finally, w...
  CRP: ...th a similar but non-significant
patients per group. A similar analysis with CRP would trend for hs-CRP (P=0.071) (Figure 3B). None of the
require 24 patients per group. Finally, we determined if biomark...
  CRP: ...if biomarkerschangedintheplaceboarm(datanot shown).
a combination of changes in calprotectin and hs-CRP The SRM in PsA patients was −1.58 for calprotectin
levels would be superior in treatment response c...
  CRP: ...ts was −1.58 for calprotectin
levels would be superior in treatment response compared and−0.75forhs-CRP.
to changes in calprotectin alone. Changes in calprotectin Second, we performed a similar biomarker...
  CRP: ...ment response an independent cohort of patients with AS without per-
butwhencombinedwithchangestohs-CRPlevelstheas- ipheralarthritisorenthesitis(n=20)receivinginfliximab
sociationtotreatmentresponsewasno...
  CRP: ...se(n=21)(C).Pairedt-testswereperformed.Dataarerepresentedasmean(standarderrorofthe
mean).*P<0.05.hs-CRP,high-sensitivityC-reactiveprotein;MMP-3,matrixmetalloproteinase-3.

--- Page 6 ---
Turinaetal.Arthr...
  CRP: ...tal.ArthritisResearch&Therapy2014,16:413 Page6of9
http://arthritis-research.com/content/16/4/413
hs-CRP (P=0.001) and calprotectin (P=0.019) serum versus−0.35±0.15μg/mlinCRP-positivepatients, witha
level...
  CRP: ...earch.com/content/16/4/413
hs-CRP (P=0.001) and calprotectin (P=0.019) serum versus−0.35±0.15μg/mlinCRP-positivepatients, witha
levelsdecreasedsignificantlyaftertwoweeksofinfliximab corresponding SRM of ...
  CRP: ...witha
levelsdecreasedsignificantlyaftertwoweeksofinfliximab corresponding SRM of −0.38 and −0.81 in CRP-negative
treatment. MMP-3 (P=0.093) showed a similar but non- andCRP-positivepatientsrespectively.F...
  CRP: ...ding SRM of −0.38 and −0.81 in CRP-negative
treatment. MMP-3 (P=0.093) showed a similar but non- andCRP-positivepatientsrespectively.Forcohort3,the
significant trend in this cohort. The SRM was −0.56 for...
  CRP: ...M was −0.56 for delta serum calprotectin levels were −0.10±0.11 μg/ml
calprotectin and −0.59 for hs-CRP. Taken together, these in CRP-negative patients versus −0.30±0.18 μg/ml in
data indicate that chang...
  CRP: ...lprotectin levels were −0.10±0.11 μg/ml
calprotectin and −0.59 for hs-CRP. Taken together, these in CRP-negative patients versus −0.30±0.18 μg/ml in
data indicate that changes in calprotectin and hs-CRP ...
  CRP: ... CRP-negative patients versus −0.30±0.18 μg/ml in
data indicate that changes in calprotectin and hs-CRP CRP-positivepatients,withacorrespondingSRMof−0.35
serum levels reflect well the response to active ...
  CRP: ...-negative patients versus −0.30±0.18 μg/ml in
data indicate that changes in calprotectin and hs-CRP CRP-positivepatients,withacorrespondingSRMof−0.35
serum levels reflect well the response to active trea...
  CRP: ...ithacorrespondingSRMof−0.35
serum levels reflect well the response to active treatment and −0.66 in CRP-negative and CRP-positive patients
withinfliximabinAS. respectively.
Serumbiomarkersoftreatmentresp...
  CRP: ...SRMof−0.35
serum levels reflect well the response to active treatment and −0.66 in CRP-negative and CRP-positive patients
withinfliximabinAS. respectively.
SerumbiomarkersoftreatmentresponseinperipheralS...
  CRP: ...SpA are magnetic resonance imaging
serum biomarkersbetween baseline and week 4 of etaner- (MRI) and CRP. MRI is able to visualize inflammatory
cept treatment in patients with peripheral SpA (cohort 3). l...
  CRP: ...axial and peripheral SpA and these lesions de-
crease in serum levels of calprotectin (P=0.032), hs-CRP crease oreven disappear upon effective treatment [33,34].
(P=0.035) and MMP-3 (P=0.045). In this co...
  CRP: ...e Accordingly, MRI is now used as a measureofinflamma-
SRM was −0.55 for calprotectin, −0.54 for hs-CRP, tion in clinical trials in AS and axial SpA. However, even
and−0.51forMMP-3.Furthermore,changesinc...
  CRP: ...tectsignificant
pre- and post-treatment changes in small PoC trials [35].
CalprotectinasabiomarkerinCRP-negativepatients The second widely used measure of inflammation in SpA
Both calprotectin and CRP ar...
  CRP: ...rinCRP-negativepatients The second widely used measure of inflammation in SpA
Both calprotectin and CRP are not highly specific to SpA </observation>
<execute>
import re
import os

tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/"

# Read each paper and analyze CRP/PTX1 context
papers = {
    "19435794": "19435794.txt",
    "25135077": "25135077.txt", 
    "30289572": "30289572.txt",
    "34903842": "34903842.txt",
    "FDA": "FDA.txt"
}

results = {}

for pmid, fname in papers.items():
    filepath = os.path.join(tmp_dir, fname)
    with open(filepath, 'r') as f:
        content = f.read()
    
    print(f"\n{'='*60}")
    print(f"PMID: {pmid}")
    print(f"{'='*60}")
    
    # Get title and abstract
    title_match = re.search(r'^(.*?)(?:\n|$)', content)
    title = title_match.group(1) if title_match else "Unknown"
    print(f"Title area: {title[:200]}")
    
    # Check for CRP mentions with context
    crp_contexts = []
    for match in re.finditer(r'.{0,150}CRP.{0,150}', content, re.IGNORECASE):
        crp_contexts.append(match.group())
    
    # Check for PTX1, Pentraxin-1, pentraxin 1
    ptx1_patterns = ['PTX1', 'PTX-1', 'Pentraxin-1', 'pentraxin 1']
    ptx1_found = False
    for pattern in ptx1_patterns:
        if re.search(pattern, content, re.IGNORECASE):
            ptx1_found = True
            print(f"Found {pattern}")
    
    print(f"PTX1 found: {ptx1_found}")
    print(f"Number of CRP contexts: {len(crp_contexts)}")
    
    if crp_contexts:
        print("\nFirst 3 CRP contexts:")
        for ctx in crp_contexts[:3]:
            print(f"  ...{ctx}...")
    
    results[pmid] = {
        'title': title,
        'has_crp': len(crp_contexts) > 0,
        'has_ptx1': ptx1_found,
        'crp_count': len(crp_contexts)
    }
    
print("\n\nSummary:")
for pmid, data in results.items():
    print(f"{pmid}: CRP={data['has_crp']}, PTX1={data['has_ptx1']}, count={data['crp_count']}")
</execute>
<observation>
============================================================
PMID: 19435794
============================================================
Title area: --- Page 1 ---
PTX1 found: False
Number of CRP contexts: 0

============================================================
PMID: 25135077
============================================================
Title area: --- Page 1 ---
PTX1 found: False
Number of CRP contexts: 72

First 3 CRP contexts:
  ...Methods: The candidate biomarkers high-sensitivity C-reactive protein (hs-CRP),interleukin-6 (IL-6), pentraxin-3...
  ...Results: Serum levels of calprotectin, hs-CRP,PTX-3, VEGF (all P<0.001) and MMP-3 (P=0.062), but not IL-6 and...
  ...decreased calprotectin (P<0.001)and hs-CRP(P<0.001)levels, witha similartrend for MMP-3 (P=0.063). The...

============================================================
PMID: 30289572
============================================================
Title area: --- Page 1 ---
PTX1 found: False
Number of CRP contexts: 17

First 3 CRP contexts:
  ...C-reactive protein(CRP) Adverseeventswithactivetreatmentwerefew,andresultedin...
  ...110ng/mLforSP-D.SerumlevelsofCRPweredeterminedby included transient ischemic enteritis in one patient and bone...
  ...test “Eiken” CRP-HG; Eiken Kagaku, Tokyo, Japan). The cut- cystitisduetoCYwereidentifiedinthisstudy....

============================================================
PMID: 34903842
============================================================
Title area: --- Page 1 ---
PTX1 found: False
Number of CRP contexts: 10

First 3 CRP contexts:
  ...withincreasingdoses.DecreasesinserumIL-6andCRPwereobservedinmostpatients.Twenty-onepatientswereevaluablefor...
  ...alternativeandlectinpathways—aswellasserumlevelsofIL-6,IL- Biomarker variables, including IL-6 and CRP, were summarised...
  ...factor α(TNFα)and C-reactive protein (CRP). treatment response were assessed using exploratory analyses....

============================================================
PMID: FDA
============================================================
Title area: --- Page 1 ---
PTX1 found: False
Number of CRP contexts: 0


Summary:
19435794: CRP=False, PTX1=False, count=0
25135077: CRP=True, PTX1=False, count=72
30289572: CRP=True, PTX1=False, count=17
34903842: CRP=True, PTX1=False, count=10
FDA: CRP=False, PTX1=False, count=0
</observation>
<execute>
import os
import re

tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/"

# Read papers with CRP and analyze the context for classification
papers_to_analyze = {
    "25135077": "25135077.txt",  # SpA biomarker study
    "30289572": "30289572.txt",  # SSc prediction study
    "34903842": "34903842.txt",  # IL1RAP antibody study
}

# Biomarker type definitions:
# 1 = PDY (Pharmacodynamic) - indicates drug effect on target/pathway
# 2 = SAF (Safety) - indicates toxicity/adverse effects  
# 3 = MOI (Monitoring) - tracks disease progression/response to treatment
# 4 = PRD (Predictive) - predicts treatment response before treatment
# 5 = SUR (Surrogate endpoint) - substitute for clinical endpoint

classifications = {}

for pmid, fname in papers_to_analyze.items():
    filepath = os.path.join(tmp_dir, fname)
    with open(filepath, 'r') as f:
        content = f.read()
    
    print(f"\n{'='*70}")
    print(f"ANALYSIS OF PMID: {pmid}")
    print(f"{'='*70}")
    
    # Extract more context around CRP
    all_crp_contexts = re.findall(r'.{0,200}CRP.{0,200}', content, re.IGNORECASE)
    
    # Get abstract section
    abstract_start = content.find("Abstract")
    abstract_end = content.find("Introduction") if content.find("Introduction") > 0 else content.find("Methods")
    if abstract_start > 0 and abstract_end > abstract_start:
        abstract = content[abstract_start:abstract_end]
    else:
        abstract = content[:2000]
    
    print("\n--- RELEVANT ABSTRACT/CONTEXT ---")
    print(abstract[:2000])
    
    # Look for key phrases indicating biomarker type
    phrases_prd = ["predict", "before treatment", "predictive", "pretreatment", "baseline"]
    phrases_moi = ["monitor", "response to treatment", "change upon", "sensitivity to change", "during treatment"]
    phrases_pdy = ["pharmacodynamic", "drug effect", "target engagement", "pathway inhibition"]
    phrases_saf = ["safety", "toxicity", "adverse", "side effect"]
    phrases_sur = ["surrogate", "endpoint", "clinical outcome", "substitute"]
    
    content_lower = content.lower()
    
    scores = {"PRD": 0, "MOI": 0, "PDY": 0, "SAF": 0, "SUR": 0}
    
    for phrase in phrases_prd:
        scores["PRD"] += content_lower.count(phrase)
    for phrase in phrases_moi:
        scores["MOI"] += content_lower.count(phrase)
    for phrase in phrases_pdy:
        scores["PDY"] += content_lower.count(phrase)
    for phrase in phrases_saf:
        scores["SAF"] += content_lower.count(phrase)
    for phrase in phrases_sur:
        scores["SUR"] += content_lower.count(phrase)
    
    print(f"\n--- SCORES ---")
    for k, v in scores.items():
        print(f"  {k}: {v}")
    
    # Determine classification based on content
    print(f"\n--- KEY CRP CONTEXTS ---")
    for ctx in all_crp_contexts[:5]:
        print(f"  ...{ctx}...")
</execute>
<observation>
======================================================================
ANALYSIS OF PMID: 25135077
======================================================================

--- RELEVANT ABSTRACT/CONTEXT ---
Abstract


--- SCORES ---
  PRD: 16
  MOI: 13
  PDY: 0
  SAF: 3
  SUR: 5

--- KEY CRP CONTEXTS ---
  ...Methods: The candidate biomarkers high-sensitivity C-reactive protein (hs-CRP),interleukin-6 (IL-6), pentraxin-3...
  ...Results: Serum levels of calprotectin, hs-CRP,PTX-3, VEGF (all P<0.001) and MMP-3 (P=0.062), but not IL-6 and...
  ...decreased calprotectin (P<0.001)and hs-CRP(P<0.001)levels, witha similartrend for MMP-3 (P=0.063). The...
  ...(−1.26),good for hs-CRP (−0.96) and moderate for MMP-3 (−0.52). Calprotectin and hs-CRP, but not MMP-3, were...
  ...Conclusions: Calprotectinand hs-CRP are good serum biomarkers with high sensitivity to change upon effective...

======================================================================
ANALYSIS OF PMID: 30289572
======================================================================

--- RELEVANT ABSTRACT/CONTEXT ---
--- Page 1 ---
doi:10.1111/1346-8138.14669 Journal of Dermatology2018; 45:1425–1433
ORIGINAL ARTICLE
Prediction of therapeutic response before and during i.v.
cyclophosphamide pulse therapy for interstitial lung disease
in systemic sclerosis: A longitudinal observational study
Hayakazu SUMIDA, Yoshihide ASANO, Zenshiro TAMAKI, Naohiko AOZASA,
Takashi TANIGUCHI, Tetsuo TOYAMA, Takehiro TAKAHASHI, Yohei ICHIMURA,
Shinji NODA, Kaname AKAMATA, Ryosuke SAIGUSA, Miki MIYAZAKI,
Yoshihiro KUWANO, Koichi YANABA, Ayumi YOSHIZAKI, Shinichi SATO
Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
ABSTRACT
Therehavebeennoestablishedparameterstopredictresponsivenesstoi.v.cyclophosphamide(IVCY)pulsether-
apyincombinationwithcorticosteroidsinpatientswithinterstitiallungdisease(ILD)relatedtosystemicsclerosis
(SSc). This retrospective study was conducted to determine predictive factors for efficacy of IVCY at the time of
before and during the treatment. Thirty-two Japanese SScpatients, ever treatedfor ILD withIVCY incombination
with prednisolone, were analyzed retrospectively. We performed detailed time-course analyses of parameters
derived from blood samples and pulmonary function tests. With the exclusion of eight unclassified patients, 24
patients were classified into 14 goodresponders (GR) or10poor responders(PR) onthe basis ofchanges inper-
cent predicted diffusing capacity for carbon monoxide (DLco). Pretreatment percent predicted DLco was signifi-
cantly reduced in PR compared with GR. In addition, serum parameters such as Krebs von den Lungen-6 (KL-6),
surfactant protein D (SP-D) and C-reactive protein were significantly higher in PR than in GR. Furthermore, our
time-course analyses revealed a transient increase in serum KL-6 levels with a peak at 3 months after the first
infusion of cyclophosphamide, which showed no relation to therapeutic efficacy. Moreover, continuously high
serum KL-6 levels (>2000 U/mL) and rapid decrease in SP-D levels 

--- SCORES ---
  PRD: 63
  MOI: 1
  PDY: 0
  SAF: 12
  SUR: 0

--- KEY CRP CONTEXTS ---
  ...C-reactive protein(CRP) Adverseeventswithactivetreatmentwerefew,andresultedin...
  ...110ng/mLforSP-D.SerumlevelsofCRPweredeterminedby included transient ischemic enteritis in one patient and bone...
  ...test “Eiken” CRP-HG; Eiken Kagaku, Tokyo, Japan). The cut- cystitisduetoCYwereidentifiedinthisstudy....
  ...offvalueforCRPwassetat3.00mg/L....
  ...apy at the end of the third CY infusion. By excluding these 194],respectively)(Fig.1b).Inaddition,serumlevelsofCRPin...

======================================================================
ANALYSIS OF PMID: 34903842
======================================================================

--- RELEVANT ABSTRACT/CONTEXT ---
--- Page 1 ---
British Journal of Cancer
www.nature.com/bjc
ARTICLE
Clinical Studies
fi
First-in-human phase 1 dose-escalation study of CAN04, a rst-
in-class interleukin-1 receptor accessory protein (IL1RAP)
antibody in patients with solid tumours
✉
DebbieRobbrecht 1 , Christiane Jungels2, Morten MauSorensen 3, IbenSpanggaard3, Ferry Eskens1, Signe ØFretland4,
Tormod KyrreGuren 4, PhilippeAftimos2, David Liberg5,Christer Svedman5, Lars Thorsson5, Neeltje Steeghs6 and AhmadAwada2
©TheAuthor(s),underexclusivelicencetoSpringerNatureLimited2021
BACKGROUND:Interleukin-1(IL-1)signallingisinvolvedinvariousprotumouralprocessesincludingproliferation,immuneevasion,
metastasisandchemoresistance.CAN04isafirst-in-classmonoclonalantibodythatbindsIL-1receptoraccessoryprotein(IL1RAP),
required for IL-1signalling. Inthis first-in-human phase1study, weassessed safety,recommended phase2dose (RP2D),
pharmacokinetics, pharmacodynamics and preliminary anti-tumouractivity of CAN04 monotherapy.
METHODS:PatientswithadvancedsolidtumoursknowntoexpressIL1RAPandrefractorytostandardtreatmentswereenrolledin
a dose-escalation study with 5dose levels (1.0–10.0mg/kg)of weeklyCAN04.
RESULTS:Twenty-twopatientswereenrolled.Mostcommonadverseeventswereinfusion-relatedreactions(41%),fatigue(32%),
constipation (27%),diarrhoea(27%),decreasedappetite (23%),nausea(23%)andvomiting(23%).Onedose limitingtoxicity was
reported.Nomaximumtolerateddosewasidentified.Pharmacokineticsanalysesindicatehigherexposuresandslowerelimination
withincreasingdoses.DecreasesinserumIL-6andCRPwereobservedinmostpatients.Twenty-onepatientswereevaluablefor
response, 43%had stabledisease per immune-relatedresponse criteria with no partial/complete responses.
CONCLUSIONS:TheIL1RAPtargetingantibodyCAN04canbesafelyadministeredtopatientsupto10.0mg/kgweekly,whichwas
definedastheRP2D. Serumbiomarkers supported target engagement andIL-1 pathway inhibition.
CLINICAL TRIAL REGISTRATION: NCT03267316.
British Journalof Cancer (2022)126:1010–1017;

--- SCORES ---
  PRD: 15
  MOI: 0
  PDY: 11
  SAF: 28
  SUR: 0

--- KEY CRP CONTEXTS ---
  ...withincreasingdoses.DecreasesinserumIL-6andCRPwereobservedinmostpatients.Twenty-onepatientswereevaluablefor...
  ...alternativeandlectinpathways—aswellasserumlevelsofIL-6,IL- Biomarker variables, including IL-6 and CRP, were summarised...
  ...factor α(TNFα)and C-reactive protein (CRP). treatment response were assessed using exploratory analyses....
  ...Serum concentrations of circulating biomarkers including CRP, Wilcoxonsigned-ranktestwasusedtoassessthestatisticalvalidity...
  ...ThebaselinemediansIL1RAPserumlevelsinstudypatientswas samples(P=0.04)andatrendindecreaseofCRPlevelsin13out...
</observation>
<execute>
import re
import os

tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/"

# Read more context from each paper with CRP to make final classifications

# Paper 25135077 - About monitoring response
with open(os.path.join(tmp_dir, "25135077.txt"), 'r') as f:
    content_251 = f.read()

# Find the Conclusions section
conclusion_match = re.search(r'Conclusions?.*?(?=\n\n|\Z)', content_251, re.IGNORECASE | re.DOTALL)
if conclusion_match:
    print("=== PMID 25135077 - Conclusions ===")
    print(conclusion_match.group(0)[:1500])

# Find sections about CRP specifically
print("\n=== PMID 25135077 - CRP key sections ===")
crp_sections = re.findall(r'.{0,300}CRP.{0,300}', content_251, re.IGNORECASE)
for section in crp_sections[:10]:
    if 'sensitivity' in section.lower() or 'change' in section.lower() or 'response' in section.lower():
        print(f"...{section}...")
        print("---")
</execute>
<observation>=== PMID 25135077 - Conclusions ===
Conclusions: Calprotectinand hs-CRP are good serum biomarkers with high sensitivity to change upon effective
treatment atthe group level insmall-scale, shortterm PoC trials in SpA.
Introduction hasimportantlimitations.First,contraindicationsandside
The use of tumor necrosis factor (TNF) blockers has effects,especiallyinpatientswithseverecomorbidity,pre-
dramaticallyimprovedthe clinical outcomeandqualityof clude the use of TNF blockers in a significant proportion
life of patients with spondyloarthritis (SpA). Originally of SpA patients. Second, TNF blockade fails to fully
implementedinankylosingspondylitis(AS)andpsoriatic control signs and symptoms of disease in a significant
arthritis (PsA), there is now increasing evidence that proportion of patients, with only 15 to 20% reaching
they are equally effective in other subtypes such as partial remission [1-6]. Third, the currently available
non-radiographic axial SpA and non-AS, non-PsA per- evidence suggests that TNF blockade fails to halt new
ipheralSpA[1-6].Nevertheless,TNFblockadeinSpAstill boneformationandankylosis[7].Finally,TNF blockade
fails to induce long-lasting drug-free remission as
diseaserelapseswithinafewmonthsoftreatmentinter-
*Correspondence:d.l.baeten@amc.uva.nl
1DepartmentofClinicalImmunologyandRheumatology,AcademicMedical ruptioninalargemajorityofpatients[8,9].
Center/UniversityofAmsterdam,Amsterdam,TheNetherlands Theselimitationsindicatethatthereisstillanimportant
2LaboratoryofExperimentalImmunology,Academic

=== PMID 25135077 - CRP key sections ===
...Methods: The candidate biomarkers high-sensitivity C-reactive protein (hs-CRP),interleukin-6 (IL-6), pentraxin-3...
---
...Conclusions: Calprotectinand hs-CRP are good serum biomarkers with high sensitivity to change upon effective...
---
...isanotherCRP-independentacute-phaseresponseprotein...
---
</observation>
<execute>
import re
import os

tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/"

# Paper 30289572 - About prediction before treatment
with open(os.path.join(tmp_dir, "30289572.txt"), 'r') as f:
    content_302 = f.read()

print("=== PMID 30289572 - Key sections ===")
# Find the abstract
abstract_match = re.search(r'ABSTRACT.*?(?=Introduction|\Z)', content_302, re.DOTALL | re.IGNORECASE)
if abstract_match:
    print("\nABSTRACT:")
    print(abstract_match.group(0)[:1500])

# Find CRP in results/discussion
crp_contexts = re.findall(r'.{0,400}CRP.{0,400}', content_302, re.IGNORECASE)
print("\n=== CRP contexts in 30289572 ===")
for ctx in crp_contexts[:5]:
    print(f"...{ctx}...")
    print("---")
</execute>
<observation>=== PMID 30289572 - Key sections ===

ABSTRACT:
ABSTRACT
Therehavebeennoestablishedparameterstopredictresponsivenesstoi.v.cyclophosphamide(IVCY)pulsether-
apyincombinationwithcorticosteroidsinpatientswithinterstitiallungdisease(ILD)relatedtosystemicsclerosis
(SSc). This retrospective study was conducted to determine predictive factors for efficacy of IVCY at the time of
before and during the treatment. Thirty-two Japanese SScpatients, ever treatedfor ILD withIVCY incombination
with prednisolone, were analyzed retrospectively. We performed detailed time-course analyses of parameters
derived from blood samples and pulmonary function tests. With the exclusion of eight unclassified patients, 24
patients were classified into 14 goodresponders (GR) or10poor responders(PR) onthe basis ofchanges inper-
cent predicted diffusing capacity for carbon monoxide (DLco). Pretreatment percent predicted DLco was signifi-
cantly reduced in PR compared with GR. In addition, serum parameters such as Krebs von den Lungen-6 (KL-6),
surfactant protein D (SP-D) and C-reactive protein were significantly higher in PR than in GR. Furthermore, our
time-course analyses revealed a transient increase in serum KL-6 levels with a peak at 3 months after the first
infusion of cyclophosphamide, which showed no relation to therapeutic efficacy. Moreover, continuously high
serum KL-6 levels (>2000 U/mL) and rapid decrease in SP-D levels (<200 ng/mL) during IVCY were remarkably
characteristic of PR and GR, respectively. ILD severity/activity before treatment and

=== CRP contexts in 30289572 ===
...C-reactive protein(CRP) Adverseeventswithactivetreatmentwerefew,andresultedin...
---
...110ng/mLforSP-D.SerumlevelsofCRPweredeterminedby included transient ischemic enteritis in one patient and bone...
---
...test “Eiken” CRP-HG; Eiken Kagaku, Tokyo, Japan). The cut- cystitisduetoCYwereidentifiedinthisstudy....
---
...offvalueforCRPwassetat3.00mg/L....
---
...apy at the end of the third CY infusion. By excluding these 194],respectively)(Fig.1b).Inaddition,serumlevelsofCRPin...
---
</observation>
<execute>
import re
import os

tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/"

# Paper 30289572 - Find results section with CRP
with open(os.path.join(tmp_dir, "30289572.txt"), 'r') as f:
    content_302 = f.read()

# Find results section
results_match = re.search(r'RESULTS.*?(?=DISCUSSION|\Z)', content_302, re.DOTALL | re.IGNORECASE)
if results_match:
    print("=== PMID 30289572 - RESULTS section ===")
    print(results_match.group(0)[:3000])

# Find discussion section
discussion_match = re.search(r'DISCUSSION.*?(?=CONCLUSION|\Z)', content_302, re.DOTALL | re.IGNORECASE)
if discussion_match:
    print("\n=== PMID 30289572 - DISCUSSION section ===")
    print(discussion_match.group(0)[:3000])
</execute>
<observation>=== PMID 30289572 - RESULTS section ===
RESULTS
GGscore)andhoneycombing(fibrosisscore,Fscore),aspre-
viously reported by Kazerooni etal.13 We added scores from Baseline characteristics
all lobes and defined the value as a representative score in Thisstudyincluded30diffusecutaneousandtwolimitedcuta-
eachpatient. neousSScpatients,whoweretreatedwithIVCYpulsetherapy,
withamixtureof30females(93.8%ofpatients)andtwomales
Efficacy assessments anddefinitions ofGR or PR (6.2% of patients). Median (25–75th percentile) age, disease
for IVCY pulse therapy duration and mRSS in total patients were 60.0years (54.3–
Patients were followed with laboratory studies, PFT and CT 67.0), 5.0years (3.0–10.8) and 13.5points (7.0–18.8), respec-
scans at time intervals, as indicated in Figures1–3 and tively (Table1). ILD was characterized by restrictive lung
legends. Especially, laboratory studies, including serum levels disease (% predicted FVC, n=29) and impairment in gas
ofKL-6andSP-D,wereperformedimmediatelypriortotheCY transfer (% predicted DLco, n=29). More detailed information
infusion during IVCY therapy. Historically, results from PFT about autoantibodies and concomitant autoimmune diseases
such as percent predicted FVC and DLco have been com- areshowninTable1.Althoughwecomparedbaselinecharac-
monly used as primary end-points in clinical reports of lung teristics between GR and PR, there were no significant differ-
diseaseinSSc.8,14However, itshould beconsideredthat FVC ences between the two groups in age, sex, disease duration,
may be improved in association with alleviation of chest skin mRSSandtypesofautoantibodies(Table1).
sclerosis by prednisolone. Therefore, in this study, efficacy of
IVCY therapy in each individual is mainly assessed by percent Relationships between pretreatment features and
predicted DLco. Furthermore, we stratified each patient to GR therapeutic response toIVCY pulse therapy in
orPR,accordingtothechangeinpercentpredictedDLcojust combination withsteroids
before and just after the first cycle of IVCY treatment (without We compared some baseline factors between 14 GR and 10
any reference to the results from second cycles of IVCY in PR. As for the pretreatment data in PFT, percent predicted
seven patients, who underwent two cycles, to exclude the DLco was significantly reduced in PR compared with GR (me-
influence of first cycle on the second one). We defined GR as dian[25–75thpercentile],46.5%[39.8–66.0%]vs69.5%[54.8–
patientswithgreaterthanorequalto6%improvement ofper- 80.5%]), while percent predicted FVC showed no significant
cent predicted DLco and PR as patients with less than 6%. differences between two groups (median [25–75th percentile],
Among the enrolled 32 patients, four had a lack of PFT data 71.5%[61.8–84.0%]vs72.5%[66.3–94.3%])(Fig.1a).Interms
beforeand/orafterIVCYtreatment,whichwasapotentiallimi- ofpretreatmentserumlevelsofILD-associatedparameters,PR
tationinouranalysis.Intwopatients,IVCYtherapiesweredis- had significantly higher levels of KL-6 and SP-D as compared
co

=== PMID 30289572 - DISCUSSION section ===
DISCUSSION
response to IVCY, the subgroup classified as GR demon-
strated an increase in percent predicted DLco during IVCY This study revealed that ILD severity and activity before IVCY
therapy (Fig.2a). On the other hand, the subgroup classified therapy are linkedto therapeuticeffects on SSc-ILD.In partic-
as PR showed no change or a decrease in percent predicted ular, patients with good improvement in DLco showed a trend
DLco during IVCY therapy. As for the changes in percent pre- toward low baseline serum levels of SP-D, KL-6 and CRP,
dicted FVC, GR showed an increasing trend during IVCY ther- compared with those with poor improvement. Furthermore,
apy,whilePRdidnotshowsuchatrend(Fig.2a).Eventhough continuoushighserumKL-6levelsandrapiddecreaseinSP-D
time-course data of serum KL-6 levels did not show any levels during IVCY therapy were observed characteristically in
apparent trends over time, seven out of 10 PR presented high PR and GR, respectively. Incidentally, although we calculated
levelsofKL-6over2000U/mL(Fig.2b).Intermsofchangesin ILD scores for the evaluation of the ILD severity in patients
SP-D,serumlevelsofSP-DinGRshowedpromptdecreaseat before IVCY therapy, ILD scores were not suitable to evaluate
2 or 3months after the first infusion of CY (Fig.2b). Further- theefficacyofIVCYduetothelowsensitivitytodetectthedif-
more, those levels from all GR finally fell under 200ng/mL. In ferences during the therapy. On the other hand, PFT for
contrasttothecaseofGR,serumlevelsofSP-DinPRdidnot patientswith SSc-ILD maybeusefultomonitordiseasestatus
demonstrate such a tendency. Most PR (8/10) showed high and response to IVCY treatment, as shown in the current
serumSP-Dlevelsover200ng/mL. study. In terms of PFT, previous studies have reported within-
subject variation, both within a testing session and between
Increase inserum KL-6levels anddecrease in testingsessions,daystoyearsapartinhealthyadultsandchil-
serum SP-D levels during IVCY pulse therapy in dren.15,16 Moreover, in adults, the within-day variation of PFT
combination withsteroids are also affected by severity of lung disease, with more varia-
Due to the lack of longitudinal laboratory data in one patient tionamongmoreseverelyillindividuals.17Therefore,itisindis-
among the enrolled 32 patients, 31 patients, including 14 GR putable that we should concurrently take notice of changes in
and10PR,wereanalyzedforbehaviorsinserumlevelsofKL- subjectivesymptoms,CTfindingsandserumparameters.
6 and SP-D over the first cycle of IVCY. Time-series curve of PatientswithSSchavethepresenceofseveralautoantibod-
serum KL-6 levels showed a transient increase with a peak at ies,someofwhichareSSc-specificantibodiesassociatedwith
3months after the first infusion of CY (Fig.3a). On the other the clinical features of this disease.18 For example, anti-topoi-
hand, that of SP-D showed a steady decrease over IVCY somerase I antibodies are associated with diffuse cutaneous
therapy (Fig.3b). Additionally, analysis of ind
</observation>
<execute>
import re
import os

tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/"

# Paper 34903842 - Pharmacodynamic biomarker
with open(os.path.join(tmp_dir, "34903842.txt"), 'r') as f:
    content_349 = f.read()

print("=== PMID 34903842 - Key sections ===")

# Find results/discussion about CRP
crp_contexts = re.findall(r'.{0,500}CRP.{0,500}', content_349, re.IGNORECASE)
for ctx in crp_contexts[:8]:
    print(f"...{ctx}...")
    print("---")

# Look for pharmacodynamic mentions
print("\n=== Pharmacodynamic/pharmacokinetic mentions ===")
pharm_mentions = re.findall(r'.{0,200}(?:pharmacodynamic|pharmacokinetic|target engagement|pathway inhibition).{0,200}', content_349, re.IGNORECASE)
for m in pharm_mentions[:5]:
    print(f"...{m}...")
    print("---")
</execute>
<observation>=== PMID 34903842 - Key sections ===
...withincreasingdoses.DecreasesinserumIL-6andCRPwereobservedinmostpatients.Twenty-onepatientswereevaluablefor...
---
...alternativeandlectinpathways—aswellasserumlevelsofIL-6,IL- Biomarker variables, including IL-6 and CRP, were summarised...
---
...factor α(TNFα)and C-reactive protein (CRP). treatment response were assessed using exploratory analyses....
---
...Serum concentrations of circulating biomarkers including CRP, Wilcoxonsigned-ranktestwasusedtoassessthestatisticalvalidity...
---
...ThebaselinemediansIL1RAPserumlevelsinstudypatientswas samples(P=0.04)andatrendindecreaseofCRPlevelsin13out...
---
...levels of sIL1RAP consistent with formation of circulating agents [42]. A rapid increase in IL-6 and CRP was seen in two...
---
...Monocytes Lymphocytes CRP...
---
...in CRP. For neutrophils the reduction was not significant (P=0.31). a WBC white blood cells; b Neutrophils; c Eosinophils; d Monocytes;...
---

=== Pharmacodynamic/pharmacokinetic mentions ===
...pharmacokinetics, pharmacodynamics and preliminary anti-tumouractivity of CAN04 monotherapy....
---
...reported.Nomaximumtolerateddosewasidentified.Pharmacokineticsanalysesindicatehigherexposuresandslowerelimination...
---
...definedastheRP2D. Serumbiomarkers supported target engagement andIL-1 pathway inhibition....
---
...andpancreaticcancer[26].Incontrast,IL1RAPexpressionislowin objectives included estimating the pharmacokinetic (PK) para-...
---
...inhibitbothIL-1αandIL-1β.Inaddition,andconsistentwitharole additionalrefinementsusingaPK/pharmacodynamic(PD)model-...
---
</observation>
<execute>
import json
import os

# Create intermediate directory for output
output_dir = "/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/"
os.makedirs(output_dir, exist_ok=True)

# Classification based on detailed analysis:
# 
# 1. Pharmacodynamic biomarker (PDY) - indicates drug effect on target/pathway
# 2. Safety biomarker (SAF) - indicates toxicity/adverse effects  
# 3. Monitoring biomarker (MOI) - tracks disease progression/response to treatment
# 4. Predictive biomarker (PRD) - predicts treatment response before treatment
# 5. Surrogate endpoint (SUR) - substitute for clinical endpoint

# Analysis:
# - 19435794: NO CRP/PTX1 mentioned - about L-FABP
# - 25135077: hs-CRP used to monitor treatment response ("high sensitivity to change upon effective treatment")
#              - Type 3: MOI (Monitoring)
# - 30289572: CRP used to predict response BEFORE treatment ("pretreatment serum levels...higher in poor responders")
#              - Type 4: PRD (Predictive)  
# - 34903842: CRP decreased with drug, "supported target engagement and IL-1 pathway inhibition"
#              - Type 1: PDY (Pharmacodynamic)
# - FDA: NO CRP/PTX1 mentioned

classifications = [
    {
        "PMID": "19435794",
        "TypeID": 0  # No CRP/PTX1 mentioned in this paper
    },
    {
        "PMID": "25135077",
        "TypeID": 3  # MOI - Monitoring biomarker (hs-CRP monitors response to treatment)
    },
    {
        "PMID": "30289572", 
        "TypeID": 4  # PRD - Predictive biomarker (CRP predicts treatment response before treatment)
    },
    {
        "PMID": "34903842",
        "TypeID": 1  # PDY - Pharmacodynamic biomarker (CRP indicates drug effect/target engagement)
    },
    {
        "PMID": "FDA",
        "TypeID": 0  # No CRP/PTX1 mentioned
    }
]

# Save to JSON
output_path = os.path.join(output_dir, "themarker_extract_1.json")
with open(output_path, 'w') as f:
    json.dump(classifications, f, indent=2)

print(f"Saved classifications to: {output_path}")
print("\nClassifications:")
for item in classifications:
    type_names = {0: "N/A (not mentioned)", 1: "PDY", 2: "SAF", 3: "MOI", 4: "PRD", 5: "SUR"}
    print(f"  PMID: {item['PMID']} -> TypeID: {item['TypeID']} ({type_names.get(item['TypeID'], 'Unknown')})")
</execute>
<observation>Saved classifications to: /root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/themarker_extract_1.json

Classifications:
  PMID: 19435794 -> TypeID: 0 (N/A (not mentioned))
  PMID: 25135077 -> TypeID: 3 (MOI)
  PMID: 30289572 -> TypeID: 4 (PRD)
  PMID: 34903842 -> TypeID: 1 (PDY)
  PMID: FDA -> TypeID: 0 (N/A (not mentioned))
</observation>
<execute>
import os
import re

tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/themarker_extract_1/"

# Re-check paper 19435794 for any CRP/PTX1 mention
with open(os.path.join(tmp_dir, "19435794.txt"), 'r') as f:
    content_194 = f.read()

print("=== Re-checking 19435794 for CRP/Pentraxin ===")
print("Paper about:", content_194[:500])

# Check all potential CRP names
patterns = ['CRP', 'C-reactive', 'C reactive', 'PTX1', 'PTX-1', 'pentraxin 1', 'pentraxin-1', 'Pentraxin-1']
for pattern in patterns:
    matches = re.finditer(pattern, content_194, re.IGNORECASE)
    for m in matches:
        print(f"Found '{pattern}' at position {m.start()}: ...{content_194[max(0,m.start()-50):m.end()+50]}...")

print("\n=== Re-checking FDA for CRP/Pentraxin ===")
with open(os.path.join(tmp_dir, "FDA.txt"), 'r') as f:
    content_fda = f.read()

for pattern in patterns:
    matches = re.finditer(pattern, content_fda, re.IGNORECASE)
    for m in matches:
        print(f"Found '{pattern}' at position {m.start()}: ...{content_fda[max(0,m.start()-50):m.end()+50]}...")
</execute>
<observation>=== Re-checking 19435794 for CRP/Pentraxin ===
Paper about: --- Page 1 ---
TheAmericanJournalofPathology,Vol.174,No.6,June2009
Copyright©AmericanSocietyforInvestigativePathology
DOI:10.2353/ajpath.2009.080780
Cardiovascular, Pulmonary and Renal Pathology
Urinary Excretion of Liver Type Fatty Acid Binding
Protein Accurately Reflects the Degree of
Tubulointerstitial Damage
Takeshi Yokoyama,* Atsuko Kamijo-Ikemori,*† functionandtheameliorationoftubulointerstitialdamage
TakeshiSugaya,*‡SeikoHoshino,*TakashiYasuda,* retards the progression of kidney disease.1

=== Re-checking FDA for CRP/Pentraxin ===
</observation>
<execute>
import json
import os

# Re-verify classifications with detailed analysis
print("=== FINAL VERIFICATION OF CLASSIFICATIONS ===\n")

# Type definitions (from ThMARs_TYPE.png):
# 1. PDY (Pharmacodynamic) - indicates drug effect on target/pathway
# 2. SAF (Safety) - indicates toxicity/adverse effects  
# 3. MOI (Monitoring) - tracks disease progression/response to treatment
# 4. PRD (Predictive) - predicts treatment response BEFORE treatment
# 5. SUR (Surrogate endpoint) - substitute for clinical endpoint

classifications_detail = {
    "19435794": {
        "TypeID": 0,
        "Reason": "No CRP/PTX1 mentioned. Paper is about L-FABP biomarker for kidney disease."
    },
    "25135077": {
        "TypeID": 3,
        "Reason": """MOI (Monitoring) - Key evidence:
        - 'hs-CRP are good serum biomarkers with high sensitivity to change upon effective treatment'
        - Used to MONITOR response to TNF blockers during treatment
        - Tracks changes over time in response to therapy"""
    },
    "30289572": {
        "TypeID": 4,
        "Reason": """PRD (Predictive) - Key evidence:
        - 'pretreatment serum parameters...CRP were significantly higher in PR than in GR'
        - 'predictive factors for efficacy of IVCY at the time of before and during the treatment'
        - CRP measured BEFORE treatment to PREDICT who will respond"""
    },
    "34903842": {
        "TypeID": 1,
        "Reason": """PDY (Pharmacodynamic) - Key evidence:
        - 'Decreases in serum IL-6 and CRP were observed in most patients' (after CAN04 treatment)
        - 'Serum biomarkers supported target engagement and IL-1 pathway inhibition'
        - CRP indicates drug's effect on IL-1 pathway (target engagement)"""
    },
    "FDA": {
        "TypeID": 0,
        "Reason": "No CRP/PTX1 mentioned in FDA document about AUDENZ vaccine."
    }
}

# Print detailed reasoning
for pmid, data in classifications_detail.items():
    print(f"PMID: {pmid}")
    print(f"  TypeID: {data['TypeID']}")
    print(f"  Reason: {data['Reason']}")
    print()

# Create final JSON output
final_output = [
    {"PMID": pmid, "TypeID": data["TypeID"]} 
    for pmid, data in classifications_detail.items()
]

# Save final result
output_dir = "/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/"
output_path = os.path.join(output_dir, "themarker_extract_1.json")

with open(output_path, 'w') as f:
    json.dump(final_output, f, indent=2)

print(f"Final output saved to: {output_path}")
print("\nFinal JSON content:")
print(json.dumps(final_output, indent=2))
</execute>
<observation>=== FINAL VERIFICATION OF CLASSIFICATIONS ===

PMID: 19435794
  TypeID: 0
  Reason: No CRP/PTX1 mentioned. Paper is about L-FABP biomarker for kidney disease.

PMID: 25135077
  TypeID: 3
  Reason: MOI (Monitoring) - Key evidence:
        - 'hs-CRP are good serum biomarkers with high sensitivity to change upon effective treatment'
        - Used to MONITOR response to TNF blockers during treatment
        - Tracks changes over time in response to therapy

PMID: 30289572
  TypeID: 4
  Reason: PRD (Predictive) - Key evidence:
        - 'pretreatment serum parameters...CRP were significantly higher in PR than in GR'
        - 'predictive factors for efficacy of IVCY at the time of before and during the treatment'
        - CRP measured BEFORE treatment to PREDICT who will respond

PMID: 34903842
  TypeID: 1
  Reason: PDY (Pharmacodynamic) - Key evidence:
        - 'Decreases in serum IL-6 and CRP were observed in most patients' (after CAN04 treatment)
        - 'Serum biomarkers supported target engagement and IL-1 pathway inhibition'
        - CRP indicates drug's effect on IL-1 pathway (target engagement)

PMID: FDA
  TypeID: 0
  Reason: No CRP/PTX1 mentioned in FDA document about AUDENZ vaccine.

Final output saved to: /root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/themarker_extract_1.json

Final JSON content:
[
  {
    "PMID": "19435794",
    "TypeID": 0
  },
  {
    "PMID": "25135077",
    "TypeID": 3
  },
  {
    "PMID": "30289572",
    "TypeID": 4
  },
  {
    "PMID": "34903842",
    "TypeID": 1
  },
  {
    "PMID": "FDA",
    "TypeID": 0
  }
]
</observation>
<execute>
# Verify the output file exists and has correct content
import json
import os

output_path = "/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/themarker_extract_1.json"

# Check file exists
if os.path.exists(output_path):
    with open(output_path, 'r') as f:
        content = json.load(f)
    print(f"✓ File exists: {output_path}")
    print(f"✓ Content is valid JSON with {len(content)} entries")
    print("\nContent:")
    for item in content:
        print(f"  {item}")
else:
    print("✗ File not found")
</execute>
<observation>✓ File exists: /root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/themarker_extract_1.json
✓ Content is valid JSON with 5 entries

Content:
  {'PMID': '19435794', 'TypeID': 0}
  {'PMID': '25135077', 'TypeID': 3}
  {'PMID': '30289572', 'TypeID': 4}
  {'PMID': '34903842', 'TypeID': 1}
  {'PMID': 'FDA', 'TypeID': 0}
</observation>
Each response must include thinking process followed by either <execute> or <solution> tag. But there are no tags in the current response. Please follow the instruction, fix and regenerate the response again.
**Thinking Process:**

I have completed the analysis of all 5 literature files for CRP (PTX1) biomarker classification. Here's the summary of my work:

**Plan Checklist:**
1. [✓] Created the intermediate storage directory
2. [✓] Read the ThMARs_TYPE.png (though OCR failed, used existing text files)
3. [✓] Read and analyzed each PDF file to classify CRP (PTX1)
4. [✓] Compiled the results into JSON format
5. [✓] Saved the final JSON file to the specified path

**Analysis Summary:**
- **19435794.pdf**: No CRP/PTX1 mentioned. Paper is about L-FABP biomarker for kidney disease.
- **25135077.pdf**: CRP is used as a **Monitoring biomarker (MOI, TypeID=3)** - "hs-CRP are good serum biomarkers with high sensitivity to change upon effective treatment" - tracks response during treatment.
- **30289572.pdf**: CRP is used as a **Predictive biomarker (PRD, TypeID=4)** - "pretreatment serum parameters...CRP were significantly higher in PR than in GR" - predicts response before treatment.
- **34903842.pdf**: CRP is used as a **Pharmacodynamic biomarker (PDY, TypeID=1)** - "Decreases in serum IL-6 and CRP were observed" and "supported target engagement and IL-1 pathway inhibition" - indicates drug effect.
- **FDA.pdf**: No CRP/PTX1 mentioned. Document is about AUDENZ vaccine.

The output file has been saved successfully to the required path.

<solution>
[
  {
    "PMID": "19435794",
    "TypeID": 0
  },
  {
    "PMID": "25135077",
    "TypeID": 3
  },
  {
    "PMID": "30289572",
    "TypeID": 4
  },
  {
    "PMID": "34903842",
    "TypeID": 1
  },
  {
    "PMID": "FDA",
    "TypeID": 0
  }
]
</solution>